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 Abbreviations 
AIM   Apoptosis inhibitor of macrophage  
ALCAM  Activated leucocyte adhesion molecule 
APC   Antigen Presenting Cell 
BAbs   Blocking antibodies 
BMI    Body Mass index 
CCL21   Chemokine (F-C-motif) ligand 21 
CDMS  Clinically definite multiple sclerosis  
CIS    Clinical isolated syndrome 
CNS    Central Nerve system 
CXCL16   Chemokine (C-X-C) ligand 16 
CSF    Cerebrospinal fluid 
DMT    Disease modifying drugs 
EAE   Experimental autoimmune encephalomyelitis 
EDSS   Expanded Disability Status Scale 
HLA   Human leucocyte antigen 
IFNβ   Interferon Beta 
IL1-Ra   Interleukin 1 receptor 
IR    Insulin resistance 
IL-6    Interleukin 6 
MMP-9   Matrix metalloproteinase 9 
MS    Multiple sclerosis 
MRI    Magnetic resonance imaging 
NAbs   Neutralizing antibodies 
NEDA   No evidence of disease activity 
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NMO    Neuromyelitis optica 
OCB    Oligoclonal bands 
OPN    Osteopontin 
OPG    Osteoprotegerin 
OR    Odds ratio 
PDDS   Patient Determined Disease steps 
PPMS   Primary progressive multiple sclerosis 
PTX3   Pentraxin 3 
ROS    Reactive oxygen species 
RRMS   Relapsing-remitting multiple sclerosis 
sTNF-R1   Soluble tumor necrosis factor receptor 1 
SPMS   Secondary progressive multiple sclerosis 
TGFβ   Transforming growth factor beta 
TNFα   Tumor necrosis factor alfa 




Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central 
nervous system (CNS), likely caused by an interaction of genetic and environmental 
factors. Epstein-Barr virus infection, low serum vitamin D levels, smoking and obesity 
increase the risk of MS. However, knowledge of their effect on disease activity and 
progression have been limited. 
 
Objective: The main objective was to explore the role of different environmental and 
lifestyle factors for MS disease activity. In more detail, we sought to evaluate whether 
there is an association between tobacco use or body mass index (BMI) and MS disease 
activity. We also explored the potential of two adipokines, leptin and adiponectin as 
biomarkers for disease course or interferon-beta (IFNβ) treatment response in MS. 
 
Methods: All data in our studies were based on the OFAMS study, a randomized 
placebo-controlled multicenter study of 92 patients with relapsing-remitting MS 
(RRMS) that was conducted between 2004 -2008. The patients were followed for 24 
months with repeated magnetic resonance imaging (MRI) of the brain, blood tests and 
clinical evaluations, 6 months prior to and 18 months during IFNβ-treatment.  
For the current thesis, we analyzed serum samples for cotinine, a biomarker for tobacco 
use, and the adipokines leptin and adiponectin. For the first study, the patients were 
categorized as tobacco-users and non-tobacco-users according to their serum cotinine 
level. For the second and third study, patients were categorized based on the World 
Health Organisation (WHO) classification of BMI into three groups; normal weight 
patients (BMI< 25 kg/m²), overweight patients (BMI 25-30 kg/m²) and obese patients 
(BMI >30 kg/m²). All analyses were adjusted for age, gender and BMI. 
 
Results: We did not find any association between tobacco use and MRI activity (paper 
I).  Further, there was no difference between tobacco users and non-tobacco users 
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regarding baseline Expanded Disability Status Scale (EDSS) score, EDSS-progression 
or relapse-rate. For tobacco users, there was no correlation between serum cotinine 
levels and disease activity.  
There was no difference in clinical and MRI activity between patients stratified by BMI 
prior to IFNβ-treatment. During IFNβ-treatment, 80 % of overweight or obese patients 
had MRI activity compared to 48 % in the group of normal weight patients (p=0.001). 
The number of patients obtaining NEDA (no evidence of disease activity)-status 
differed according to BMI; 26 % in the normal weight group compared to only 13 % 
in the group of overweight and obese patients (p=0.05) (paper II).  
There was no association between serum levels of leptin or adiponectin and MRI 
disease activity (paper III). The serum levels of leptin were lower and the levels of 
adiponectin higher during IFNβ-treatment compared to the treatment-naïve period, 
reflecting the anti-inflammatory effect of the drug. 
 
Conclusion: In our studies, we found no direct association between tobacco use or 
BMI and MS disease activity. During IFNβ-treatment fewer of the overweight and 
obese patients obtained NEDA-status compared to patients with normal weight, 
indicating that BMI could affect IFNβ-treatment response. Serum levels of leptin and 
adiponectin seem not to be suited as biomarkers for disease activity or IFNβ-treatment 
response in MS. 
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1. Introduction  
 
Multiple sclerosis (MS) is an immune mediated disease of the central nervous system 
(CNS) characterized by inflammatory demyelination and axonal degeneration. The 
disease was first described in 1868 by a French neurologist, Dr. Jean-Martin Charcot 
[1] emphasizing three typical, but not pathognomonic clinical features of MS; intention 
tremor, nystagmus and scanning speech [2]. MS primarily affects young adults, 
typically presenting with subacute episodes of neurological deficits. The symptoms 
vary greatly according to the area of the demyelinating lesions in the CNS, but typical 
manifestations are visual disturbances, sensory loss, limb weakness and gait ataxia [3]. 
The exact cause of MS is still not known, but genetic factors in combination with 
environmental and/or lifestyle factors are probably involved [4, 5].  
1.1 Pathogenesis 
The major pathological mechanisms in MS are inflammation, demyelination and 
axonal degeneration. Initially the disease is predominated by an inflammatory process 
and presence of immune cells in the CNS [6]. As the disease evolves, the inflammation 
becomes less prominent and the pathological process consists mostly of 
neurodegeneration and sclerosis. The main neuropathological features of MS are 
demyelinated areas in the white and grey matter of the brain and spinal cord known as 
plaques, associated with axonal loss, and later brain atrophy [6, 7].  
1.2 Descriptive epidemiology 
The global prevalence of MS is estimated to vary from approximately 50-300 per 
100.000 people [3]. A distinctive epidemiological feature of MS is an increasing 
prevalence with increased distance from the equator. Norway has a high prevalence of 
MS with around 200 patients per 100,000 and an incidence of about 8-10 per 100,000 
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[8, 9]. As for many autoimmune diseases there is a clear female to male ratio, and 
women’s hazard of MS is about three times greater than for males [10]. 
 
Figure 1. Global prevalence of MS in 2020 
The figure illustrates the distribution of MS across the world with prevalence 
reported per 100.000 population. Reproduced with permission from Multiple 
Sclerosis International Federation-Atlas of MS-3rd Edition (September 2020). 
 
1.3 Clinical characteristics 
The disease onset is for most patients in the early adulthood. The patients typically 
present with loss of a neurological function depending on the location of the CNS 
lesion. Common presenting symptoms are; unifocal vision disturbances caused by 
optical neuritis, sensory symptoms, motor weakness, gait disturbance and bladder 
problems. The typical disease course consists of repeating subacute episodes of clinical 
 15 
symptoms followed by symptom remission [3, 11]. The disease severity and relapse 
frequency is heterogenous and unpredictable at disease onset.  
1.4 Diagnosis 
MS is diagnosed based on a work-up of anamnestic information, clinical evaluation 
and additional tests including MRI and cerebrospinal fluid (CSF) analyses [12, 13]. 
The clinical neurological examination aims at detecting dissemination of disease in 
time and space. MRI T2-weighted scans show hyper-intensity (white) lesions in the 
CNS. CSF can be analysed for oligoclonal bands (OCB), indicating abnormal 
inflammatory response in the brain. Different classification and diagnostic criteria has 
been proposed over the years, but the current established diagnostic criteria for MS 
are “the McDonald Criteria”, recently revised in 2017 [12]. 
Relapsing-remitting multiple sclerosis 
Number of clinical 
attacks 
Number of lesions 
with objective clinical 
evidence 
Additional data needed for a 
diagnosis of MS 
≥ 2 clinical attacks ≥ 2 None 
≥ 2 clinical attacks 
1 (and a clear-cut 
historical evidence of a 
previous attack involving 
a lesion in a distinct 
anatomical location) 
None 
1 clinical attacks ≥ 2 
Dissemination in time demonstrated by an 
additional clinical attack or by MRI  
OR  
Demonstration of CSF-specific 
oligoclonal bands. 
1 clinical attack 
(Clinical isolated syndrome 
(CIS)) 
1 
Dissemination in space demonstrated by 
an additional clinical attack implicating a 
different CNS site or by MRI  
AND  
Dissemination in time demonstrated by an 
additional clinical attack or by MRI  
OR  




Table 1. The revised McDonald criteria 2017 [12].  
The 2017 McDonald criteria for diagnosis of MS in patients with an attack at onset 
(Relapsing-remitting MS) and by progression from onset (Primary progressive MS). 
 
1.5 Classification of MS 
There are different subgroups or phenotypes of MS depending on the clinical 
presentation and course. In 1996 the US National Multiple Sclerosis Society (NMSS) 
Advisory Committee on Clinical Trials in Multiple Sclerosis defined four different 
forms of MS;  relapsing-remitting (RR), secondary progressive (SP), primary 
progressive (PP), and progressive relapsing (PR) [14]. Since the knowledge of disease 
pathology and mechanisms has evolved, the classification was revised in 2013 [15]. 
The new classification has emphasized disease activity, defined as relapses or MRI 
findings and disease progression. The new term “clinical isolated syndrome” was 
added as a subgroup and in addition all forms was subcategorized as active or non-
active [16].  
 
 
Primary progressive multiple sclerosis can be diagnosed in patients with:  
 1 year of disability progression (retrospectively or prospectively determined) independent of 
clinical relapse 
Plus two of the following criteria: 
 One or more T2-hyperintense lesions characteristic of MS in one or more of the following 
brain lesions: periventricular, cortical or juxtacortical, or infratentorial 
 Two or more T2-hyperintense lesions in the spinal cord 
 Presence of CSF-specific oligoclonal bands 
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1.5.1 Relapsing-remitting MS (RRMS) 
The most common form of MS is relapsing-remitting MS presenting with repeated 
clinical relapses. A clinical relapse is defined as; “A monophasic clinical episode with 
patient-reported symptoms and objective findings typical of multiple sclerosis, 
reflecting a focal or multifocal inflammatory demyelinating event in the CNS, 
developing acutely or sub-acutely, with a duration of at least 24 hours, with or without 
--recovery, and in the absence of fever or infection” [12]. The first single demyelinating 
episode is termed a clinically isolated syndrome (CIS) [17]. Most patients will have a 
second episode and be diagnosed with clinically definite multiple sclerosis (CDMS) 
[18]. The risk of CDMS is associated with number of MRI lesions, the presence of 
oligoclonal bands in the CSF,  and inversely associated with age at CIS onset [17]. 
Patients with current brain lesions and oligoclonal bands in CSF have an 86 % risk of 
CDMS after a five year follow-up [18]. For patients diagnosed with RRMS the disease 
course is individual and unpredictable. Some patients have an aggressive disease with 
multiple MRI lesions and frequent clinical relapses, while others may not have another 
relapse for years. RRMS will for many patients develop into a secondary progressive 
MS (SPMS) in time. SPMS is characterized by a gradually increasing disease load and 
absence of the typical relapsing-remitting flow. There are no clear clinical, imaging, 
immunologic or pathologic criteria for the transition point to SPMS, and the diagnosis 




Figure 2. The 1996 and 2013 definition of MS subgroups for relapsing-remitting 
disease [16].*Activity determined by clinical relapses and/or MRI activity (contrast-
enhancing lesions; new or unequivocally enlarging T2 lesions assessed at least 
annually); if assessments are not available, activity is “indeterminate”. ** CIS, if 
subsequently clinically active and fulfilling current multiple sclerosis (MS) diagnostic 
criteria, becomes relapsing-remitting MS (RRMS).  Permission to reproduce 
according to Creative Commons Attribution licence 3.0. 
 
1.5.2 Primary progressive MS (PPMS) 
About 10-15 % of MS patients present with a gradually progressive load of symptoms 
with no clear relapses, and are diagnosed with primary progressive MS (PPMS) [3]. 
Unlike RRMS, PPMS is often diagnosed in patients that are 50-60 years old, and there 
is no evident gender ratio [19]. The most common clinical presentation is progressive 
spastic paraparesis [20]. Since PPMS is mostly dominated by a neurodegenerative 
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process, and not inflammation, most of the therapeutic choices in MS are ineffective in 




Figure 3. The 1996 and 2013 definition of MS subgroups for progressive disease 
[16]. * Activity determined by clinical relapses assessed at least annually and/or MRI 
activity (contrast-enhancing lesions; new and unequivocally enlarging T2 lesions). 
**Progression measured by clinical evaluation, assessed at least annually. If 
assessments are not available, activity and progression are “indeterminate”. 
Permission to reproduce according to Creative Commons Attribution licence 3.0. 
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1.6 Treatment  
There is no curable treatment for MS, but several immunomodulatory medications can 
reduce disease activity and disability progression [11, 21]. Most medications have been 
proven effective in RRMS, but so far few have shown an effect in slowing progression 
of PPMS [22]. All medications are mainly based on the same principle; to reduce the 
inflammatory burden by inhibiting the immune response. The medications are referred 
to as disease modifying therapies (DMT) [3]. Some medications are self-administred 
either as tablets (fingolimod, dimethyl fumarate, teriflunomide, cladribine, ozanimod, 
siponimod) or as subcutaneously or intramuscular injections (IFNβ and glatiramer 
acetate), while others are infused at the hospital (alemtuzumab, natalizumab, rituximab, 
ocrelizumab). All DMTs except cladribine are administrered as the same dosage for all 
patients, regardless of BMI. For the distinct choice of medication there are two 
therapeutic approaches; 1) escalation-strategy starting with a moderately effective 
medication and escalating to a more effective DMT if the patient presents with new 
signs of disease activity, and 2) induction-strategy starting with a higly effective 
therapy at once [3]. A few patients with an aggressive disease and poor response to 
DMTs may be offered autologous hematopoietic stem cell treatment [23]. During acute 
relapses the patients may benefit of intravenous high-dosage steroid treatment and in 
some cases plasma exchange [3].  
Many MS patients suffer from different symptoms that affect their quality of life such 
as fatigue, cognitive impairment, spasticity, pain, impaired ambulation and bowel-, 
bladder-, and sexual-dysfunction [3]. There is often a need for a multidisciplinary 
approach including different medications, exercise, physiotherapy and cognitive 
rehabilitation. 
Modifiable environmental factors also seem to play a part in the disease control [24]. 
So far, vitamin D supplements and smoke cessation is recommended [25]. It is possible 
that the maintenance of normal body weight and a healthy diet can have a beneficial 
effect on the disease course via immunological mechanisms, but this need further 
studies.   
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For evaluating and optimizing the DMT, the term NEDA -“no evidence of disease 
activity” has been introduced as an outcome measure in MS [26, 27]. When the term 
was first introduced, NEDA was defined as a composite of no relapses, no EDSS-
progression and no MRI activity (new or enlarging T2-lesions or Gd-enhancing 
lesions). The description for an ideal treatment goal was based on data collected in 
clinical trials [28, 29]. With this approach the inflammatory component of the disease 
was emphasized and not the ongoing neurodegenerative damage. Other parameters was 
therefore suggested to be added including brain volume, neurophysiological  outcomes 
like cognitive function, and neurofilament levels in blood or CSF [26, 30].The term 
NEDA-4 was introduced including the absence of MRI brain atrophy [31]. Recently, 
neurofilament in CSF has been demonstrated as a useful biomarker of disease activity, 
and are suggested incorporated in the term NEDA-5 [32]. It is likely that the definition 
of NEDA will evolve in the future including more measurements. 
 
 
Figure 4. NEDA-4.  
Illustration of the optimal therapeutic goal in MS, no evidence of disease activity. For 
each step in the pyramid the patient has no sign of the disease activity parameter 
illustrated, hence a more optimal treatment response.  
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1.7 Prognosis 
The MS disease course is unpredictable. Some patients have a “benign MS” with one 
or a few clinical attacks during the whole disease span, while others experience a large 
disease load within just a few years. There are, however, some useful prognostic 
factors. Older age at time of diagnosis, male gender, frequent relapses initially and 
presence of lesions in the spinal cord are all considered predictors of a higher risk of 
disability accumulation and progressive disease [33]. A high baseline MRI lesion load 
and oligoclonal bands in the CSF are factors highly predictive of conversion of CIS to 
MS [18].  
Recent therapeutic developments have substantially improved the long-term prognosis 
for MS patients, with a possibility to halt or slow down disease progression a longer 
time period before transition to SPMS. In a recent study, only 10 % of MS patients had 
an EDSS ≥6, 15 years after the diagnosis, compared to more than 50 % in earlier studies 
[34].  
Autologous hematopoietic stem cell treatment in MS has shown very promising results 
with >70 % of the patients obtaining NEDA-3-status 10-year post-treatment [35]. 
Nevertheless, there is still no curable treatment, and even with less disability the 
patients struggle with other symptoms. This is reflected by the fact that working status 
among MS patients have changed little over time. In a recent study more than 80 % of 
the patients were unemployed 10 years after being diagnosed with MS [36].  
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2. Risk factors for MS 
MS is most likely caused by an interaction of genetic and environmental factors [37-
39]. Although much is still unknown, the scientific evidence so far supports the 
hypothesis of a genetic susceptible individual exposed to one or more environmental 
events that trigger the development of the disease. The role of genetics in MS was early 
recognized through familial aggregation [40], but the difference in MS prevalence by 
latitude and the results of migration studies made it evident that also environmental 
factors are involved [41, 42].  
The prevalence of MS has increased over the last decades, to a greater extent than what 
can solely be explained by better diagnostics [43]. This has encouraged the search of 
other environmental risk factors in addition to the established factors Epstein-Barr virus 
(EBV), smoking, obesity and vitamin D. Excessive intake of salt, organic solvents, air 
pollution, western diet and shift work are factors suggested to possibly increase the risk 
of MS, whereas alcohol use, excessive physical activity, cytomegalovirus infection, 
snuff (oral tobacco) and high coffee consumption may possibly reduce the risk [4, 44-
53]. As MS is a chronic disease with an unpredictable course, recognizing risk factors 
and focusing on disease prevention is important.  
 
 
Figure 5. MS is caused by interaction of several factors. 
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2.1 Genetics 
MS is not considered a genetic disease, but the role of genetics in MS were early known 
through twin studies. The concordance rate for monozygotic twins is around 25-30 % 
whereas dizygotic twins and other siblings have a risk of 2-5 % [54, 55]. The lifetime 
risk for individuals with northern European ancestry is about 0,1-0,2 % [54]. The risk 
of MS is strongest associated with alleles of the human leukocyte antigen (HLA), and 
genotypes in the HLA locus have been found to account for as much as 30 % of the 
genetic susceptibility in MS [56, 57]. Changes in amino-acid positions in the peptide-
binding groove of the HLA-molecule affect the recognition and binding of antigens 
[58]. Patients with the genotype DRB1*1501 are three times more likely to develop 
MS than non-carriers, [3] and for homozygous carriers the risk increases six-fold [59]. 
Also HLA DRB1 *1303, *0404, *0401 and *1401 are associated with MS, in addition 
to a great number of other immune-related risk alleles, many connected with the role 
of regulatory T cells [60]. Genome-wide association studies (GWAS`s) have until now 
identified more than 200 genetic regions associated with MS outside of the HLA [58, 
61]. Interestingly, some environmental and lifestyle factors have shown interactions 
with genetic risk loci leading to an increased disease risk [4, 62-64].  
 
2.2 Environmental risk factors 
Several environmental factors are associated with MS, and many of them seem to affect 
both MS risk and the disease course. The exact pathogenetic mechanisms for their 
interplay are plural and not well known, but it is likely that all assess their impact 
through ways of affecting the immune system [38].  
 25 
 
Figure 6. Overview of different risk factor for MS.  
Genetic and environmental factors affect the risk of MS. Some of the possible 
pathogenetic mechanisms are illustrated. 
 
2.2.1 Epstein-Barr virus 
Epstein-Barr virus (EBV) and infectious mononucleose was the first, and has since 
been the strongest environmental factor known to be associated with MS [65, 66]. 
Many studies indicate that EBV exposure is required for the development of MS, and 
this was emphasized in a longitudinal study following seronegative military personnel, 
demonstrating that all became EBV seropositive before MS onset [67, 68]. EBV is 
consistently associated with MS risk across different regions and ethnic groups [69]. 
Higher Epstein-Barr nuclear antigen-1 antibody serum levels are associated with an 
increased MS risk [70, 71]. The antibody levels in serum may also affect the MRI 
disease activity, [72, 73] although the results of different studies are conflicting [74-
76]. The immunopathological mechanism connecting EBV and MS are not well 
understood. A study exploring brain tissue described evidence of EBV-infection in 
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brain-infiltrating B-cells, and hypothesized that EBV-infected autoreactive B-cells 
enter and accumulate in the CNS, where they produce antibodies and stimulate 
autoreactive T-cells [77]. Other explanations may be molecular mimicry between EBV 
and myelin antigens or a general inflammation caused by EBV leading to bystander 
damage in CNS [66, 78].  
 
2.2.2 Vitamin D 
Vitamin D was suspected early on to play a part in MS due to the increasing MS 
incidence with increased latitude, as sunlight exposure is the main factor for vitamin D 
serum levels, along with a diet of fatty fish. Over the years, a large body of evidence 
suggests a likely role for vitamin D in MS [79]. A large study of American soldiers 
showed an association between 25(OH)D serum levels and the risk of MS, where 
individuals with the highest serum levels had a 62 % lower risk [80]. Similar findings 
were also reported in a Swedish study [81]. The serum level in newborns seem to 
influence the risk of MS in later life, with lower MS risk for newborns with higher 
25(OH)D levels [82]. Several studies show the benefit of vitamin D supplementation 
to prevent MS disease later [83-85]. Also genetic factors influencing vitamin D 
metabolism has been associated with MS risk [86].  
Furthermore, vitamin D levels seem to affect the disease course in MS. Higher serum 
levels are associated with decreased MRI activity, [87-89] and a lower number of 
relapses [87, 90]. The role of vitamin D may be explained by its immunemodulatory 
capacity to increase and stimulate regulatory T-cells and promote an anti-inflammatory 
serum cytokine profile, priming the immune system towards an anti-inflammatory state 
[91, 92]. Several studies have described a beneficial immunological response of 
vitamin D supplementation for MS patients [25, 93, 94]. However, two recent 
randomized studies did not find a clear effect of highdose Vitamin D3 supplementation 
as add-on to DMTs on disease progression, although supplementation had beneficial 
effects regarding MRI activity [95, 96]. Daily vitamin D supplementation is advised 
for all MS patients [25].  
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2.2.3 Tobacco smoking 
Smoking is a well established environmental risk factors for MS [65, 97-99]. Although 
a widespread habit worldwide, smoking is more prevalent among MS patients than in 
the general population [100, 101]. Three large prospective studies on women all found 
that smoking of more than 15 cigarettes a day was associated with an increased risk of 
MS, with a relative risk in the studies varying from 1.4 to 1.7 [102, 103]. A Swedish 
study found similar results for men [104]. Further, several case-control studies have 
reported an association [105-108], although a few found contradictive results [109, 
110]. The serum levels of cotinine, a nicotine metabolite and biomarker for tobacco 
use, are also associated with MS risk [99]. A large meta-analysis concluded that 
smoking increase the MS risk by more than 50 % [111]. The association was stronger 
for men and for current smokers than for previous smokers, and in addition there is a 
dose-response relationship between smoking habits and MS [111, 112]. Passive 
smoking also increases the risk of MS, with an increased risk the longer the duration 
of exposure [113].  
Tobacco use is associated with a more severe disease course in MS [114-116]. In CIS, 
smoking has been shown to increase the MRI activity and cause an earlier conversion 
to CDMS [117, 118]. A number of studies report a more rapid disease progression in 
smoking patients, and the progression is positively correlated to cigarette consumption 
[115, 119-121]. A study found that smokers reached EDSS scores of 4 and 6 
significantly faster than non-smokers [115]. Interestingly, for ex-smokers the disease 
progression-rate was not higher than for the non-smokers. The conversion from RRMS 
to SPMS has also been reported to be promoted in smokers [122]. A study that followed 
179 MS patients for more than five years found a 3.6 times higher risk of convertion to 
SPMS among smokers compared to never-smokers [122]. Although most studies 
confirm an association with disease progression, there have been contradictory results 
[123]. In a Dutch survey of 364 MS patients, smoking habits did not influence disease 
progression, and an American study found no association between serum cotinine 
levels and MS disease progression [124, 125].  
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The mechanism of how smoking increases MS disease progression and conversion to 
SPMS is not clear, but possible explanations could be increased inflammation and 
disease activity or degenerative processes [122, 126]. Relatively few studies have 
explored the role of tobacco use in inflammatory disease activity in MS, and the results 
have been conflicting [119, 125, 127-129].  Some studies report no association between 
smoking and relapse rate, while two studies of patients with CIS found increased MRI 
activity among smokers [118, 119, 128, 130]. Smoking is reported to increase the lesion 
load and brain atrophy in MS patients, and serum levels of neurofilament, a biomarker 
of neuroaxonal injury is also increased in smoking MS patients [131-136].  
The pathogenetic mechanisms of smoking in autoimmune diseases are numerous [137, 
138]. Tobacco smoking has a profound effect on the immune system, by its many ways 
of stimulating towards a pro-inflammatory immune state in addition to several immune 
suppressive effects [126, 139, 140]. The components of smoke have an impact on the 
immune-cell subsets causing elevated circulatory T-cells and augmented auto-reactive 
B-cell activity and a dysfunction of antigen-presenting cells (APC) [139, 141]. In 
addition, pro-inflammatory cytokines are increased. This may lead to CNS 
inflammation and a direct toxicity on neurons. Recent research results indicate that 
smoking lead to a dysregulation in gene expression in peripheral blood cells which may 
contribute to CNS inflammation [137]. A study showed that two systems affected by 
smoking, the renin-angiotensin system and indoleamine 2, 3-dioxygenase activity lead 
to reduced number of regulatory T-cells in MS [142]. Tobacco smoking further affects 
the antigen exposure due to tissue hypoxia and cellular necrosis. There may also be a 
direct injury on the blood brain barrier (BBB), whereas nitric oxide contribute to BBB 
dysfunction [137]. Tobacco smokers have increased serum levels of metalloproteinase-
9 that are known to promote migration of autoreactive immune cells across the BBB 
[143]. Nicotine has been shown to increase the BBB permeability, but may also cause 
beneficial effects in MS by inhibiting immune responses, hence causing an anti-
inflammatory effect [44]. Some studies also report that nicotine may possess a 
protective effect in Experimental autoimmune encephalomyelitis (EAE) [144-146]. It 
is thereby likely that the main acting agent causing the CNS damage in MS is not 
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primarily nicotine, but other components in tobacco. Corroborating this, a study on the 
use of oral tobacco (snuff), found a dose-dependent negative association between the 
risk of MS and oral tobacco [147], indicating that chronic lung irritation from smoking, 
and not nicotine in itself could be the cause of the association. This theory fits well 
with reports suggesting sources of lung irritation as air pollution and organic solvents 
to increase the risk of MS [47, 50, 148-151]. Results from animal studies also 
emphasize the importance of the mode of delivery as autoreactive T-cells were found 
to be activated in the lungs in EAE mice [152].  
 
 
Figure 7. The effect of smoking.  
Illustration of several possible mechanisms of how smoking may affect the immune 
system and contribute to autoimmunity. Reproduced with permission from Springer 
nature, Copyright © 1969, Nature Publishing Group [153]. 
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2.2.4 Obesity       
 
The World Health Organization (WHO) defines obesity as an excessive fat 
accumulation that presents a risk to health. Individuals with body mass index (BMI) 
>25-30 are considered to be overweight, and individuals with BMI >30 are obese. 
Obesity is associated with cardiovascular diseases, cancers and autoimmune diseases 
[154, 155]. The epidemic of obesity is one of the worlds` greatest public health 
challenges. More than 1.9 billion people were estimated as overweight and obese in 
2015, and the numbers are increasing [156]. Both high and low prevalence of obesity 
among MS patients are reported [157-159], but a recent meta-analysis describes in 
general lower mean BMI in MS patients than in healthy controls [160].  
 
Figure 8. The WHO classification of BMI 
Reprinted by permission from Getty images (www.everydayhealth.com)  
 
Obesity in youth is associated with increased risk of MS [161]. An American study on 
two large cohorts of nurses and a Swedish case control study (EIMS=Epidemiological 
Investigation of MS) both found a 2-fold increased MS risk for individuals with higher 
BMI (>27 and ≥30 kg/m2) at age 18-20 years [162, 163]. Other studies have shown an 
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association between obesity in childhood and MS. In a large Danish study of more than 
300.000 school children, higher BMI in childhood and early adolscence was associated 
with an increased MS risk, especially in girls [164]. A recent German study found that 
obesity in childhood was associated with a twofold odds of MS in both genders, [165] 
and another study in California describe similar results [166]. Birth weight is, however, 
not associated with MS risk [164]. A study using recalled body size instead of 
objectively measured BMI also confirmed a positive association between obesity and 
MS risk [167]. Only one early study found a possible inverse association between high 
BMI and MS risk, but this might have been associated to recall bias [168].  
The link between obesity and MS risk may be via vitamin D, which is fat soluble. 
Obese individuals have more vitamin D sequestered in their fatty tissue making less 
available in the blood [169-171]. It is currently debated to which extent obesity itself 
increases MS risk, or whether obesity mainly is a proxy for low serum vitamin D levels 
or other factors related to overweight and obesity. Findings in a recent study provide 
evidence for both an independent and a causal effect between vitamin D level and 
obesity as risk factors in MS [172]. Inherited genetic variations influencing BMI have 
been found to be associated with MS, supporting a causal effect of increased BMI on 
susceptibility to MS [173, 174]. There is also an interaction between obesity and HLA 
antigen MS risk variants, and a study demonstrated a sevenfold increase in MS risk of 
obese MS patients with the HLA-DRB1*15 allele compared to non-carriers [64]. 
Relatively few studies have addressed the role of obesity for the MS disease course. In 
an American study, obesity among female MS patients was associated with a higher 
risk of a relapsing disease course at disease onset [175], but in a more recent study, 
BMI did not influence the risk of relapses [176]. However, a non-significant trend of 
higher annual relapse rate among overweight and obese children with MS have been 
reported [177].  
A study found that higher BMI was associated with higher EDSS and another study 
found the same result for female patients [178, 179]. Another study showed higher 
disability, assessed by EDSS score, in MS patients with insulin resistance and adiposity 
 32
[180]. Studies have also found that BMI and dyslipidemi are associated with MS 
disability and disease progression [181-183]. Patients with increased waist 
circumference have been reported of a 47 % increased odds of severe disability, 
assessed by Patient Determined Disease steps (PDDS) score [184]. However, a 
previous study did not find any association between BMI and disability for MS patients 
using PDDS score [157]. 
MS patients with higher BMI are reported to have a greater reduction in brain volume, 
[185] and a study reported of worse performance in cognitive tests compared to normal 
weight patients [186]. Obese MS patients are also found to be more depressed, have 
lower functional capacity and worse self-rated health status [187, 188].  
The link between MS and obesity is still unclear, but may be attributed to mainly two 
immunological responses: a chronic systemic inflammation and activation of a humoral 
immune response triggering production of autoantibodies. White fat tissue has an 
endocrine function secreting several proinflammatory cytokines like tumor necrosis 
factor α (TNFα) and interleukin-6 (IL-6) leading to a systemic low grade inflammation 
in obese individuals. This peripheral inflammation may directly disrupt the BBB 
causing neuroinflammation [189]. The increased serum levels of cytokines, insulin and 
saturated fatty acids can also activate different cells of the CNS. An activation of 
microglia cells and astrocytes leads to further increased levels of proinflammatory 
cytokines like IL-6 and TNFα and reactive oxygen species (ROS) [190, 191].  
Apoptosis inhibitor of macrophage (AIM) is a macrophage-derived blood protein, 
increased in obese individuals, that induces release of fatty acids and chemokines from 
adipocytes leading to increased infiltration of M1-macrophages to fatty tissue. This 
causes polarization towards an unfavourable M1-macrophage profile that subsequently 
leads to an utter inflammation [192]. The increased release of fatty acid caused by AIM 
also activates the NLRP3-inflammasome that mediates caspase-1 activation and 
secretion of proinflammatory cytokines IL-1β and IL-18. This inflammasome and the 
cytokines released is thought to be involved in MS pathogenesis, and is found to have 
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a critical role for the EAE development [193, 194]. AIM form immune complexes with 
IgM and has also a role in the production of IgG autoantibodies [155]. 
Obesity causes induction of Th17-cells, a T-cell subset involved in the pathogenesis of 
autoimmune diseases. Th17-cell activities are shown to effect MS mostly through the 
secretion of proinflammatory IL-17, but also through IL-21 that effect the infiltration 
of lymphocytes in MS lesions, and IL-22 that promotes BBB damage [195, 196]. In 
addition to cytokines, fat tissue secretes a number of adipokines that can affect the MS 
pathogenesis in several ways.  
Obesity may be linked to a diet consisting of much saturated fatty acids, often referred 
to as a “Western diet”. This diet influence the immune system, causing a 
proinflammatory state in autoimmune diseases, and is suggested to be a risk factor for 
MS [49, 197]. Possible pathogenetic mechanisms involve dysbiosis in the gut 
microflora, modulation of components in the inflammatory cascade and interaction 
with regulatory T-cells [198, 199]. Animal dietary intervention studies have 
demonstrated the effect of diet in EAE. Calorie restricted mice had less disease severity 
and reduced demyelination and axonal damage, [200-202] whereas fat-diet fed mice 
had a more severe EAE with increased neuroinflammation, oxidative stress and CNS 
infiltration [195, 203, 204]. There has also been some studies indicating the beneficial 










Figure 9. The effect of obesity in autoimmune diseases. 
The figure illustrates the main mechanisms suggested for how obesity may promote 
autoimmune diseases. Reprinted by permission from Elsevier: Autoimmunity Reviews 
©. 2014 [155].  
 
2.3 Potential biomarkers of disease activity in MS 
A biomarker can be defined as “ a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” [207]. Since MS is a 
heterogenous disease with an unpredictable disease course, there is an evident need for 
biomarkers. Potential biomarkers could improve disease diagnosis, help predicting 
disease course and optimizing treatment. Multiple biomarkers have been explored in 
both serum and CSF [208, 209]. The biomarkers currently in use in MS is MRI white 
matter lesions, oligoclonal bands in the CSF and JC viral titers for natalizumab 
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treatment [208]. A possible upcoming biomarker for clinical use is serum 




Adipokines are cytokines (cell signalling proteins) or hormones secreted by the fatty 
tissue shown to play a part in the regulation of the immune system [211]. Dysregulation 
of the production and secretion of adipokines contribute to the chronic low grade 
inflammation in obesity [212]. Most adipokines drive the immune system towards a 
pro-inflammatory state, but some possess anti-inflammatory traits. The counterbalance 
between the serum levels of the different adipokines may contribute to the pathogenesis 
of different obesity-linked complications [212]. Leptin and adiponectin are the most 
abundant adipokines produced by adipocytes [211].  
Leptin  
Leptin is a proinflammatory adipokine with a potential role in the pathogenesis of 
several autoimmune disorders [213, 214]. The main function of leptin is regulation of 
metabolism by modulating feeding behaviour through the CNS, promoting satiety and 
stimulating energy expenditure. Being produced by adipocytes, it signals the body`s 
energy stores and functions as a negative feedback adipostat [215]. Serum leptin levels 
correlate with adipose mass and are 2-3 times higher in woman than in men [211, 215, 
216]. 
Leptin stimulates the proliferation and activation of monocytes by inducing production 
of cytokines like TNF-α, IL-6 and IL-1, and also stimulates the production of CC-
chemokine ligands like CCL3, CCL4 and CCL5 by macrophages [211]. Neutrophil 
chemotaxis and production of ROS are promoted in addition to activation of natural 
killer cells (NK cells) [211]. The maturation and survival of dendritic cells are also 
enhanced by leptin. Further, leptin modifies T-cell immunity by effecting T-cells and 
mononuclear cells to increase the production of Th1-type cytokines IL-2 and IFNγ and 
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suppress the production of the Th2-type cytokine IL-4, hence polarizing T-cells 
towards a Th1-cell type [217]. 
A meta-analysis of leptin levels in MS patients concluded that serum levels of leptin 
are higher in MS patients than in healthy controls [218]. In a recent study there was a 
positive association between serum leptin concentration and the risk of MS [219]. Also 
different gene variants for the LEP gene are found to be associated with susceptibility 
to MS [220]. Leptin serum levels are found to be inversely associated with the number 
of regulatory T-cells in MS patients, [221, 222] and are positively correlated to 
proinflammatory mediators [222]. Several studies have explored the role of serum 
leptin level as a biomarker in MS, with conflicting results. A study found increased 
levels before clinical relapses, and decreased levels during IFNβ-treatment [223], while 
others have described higher levels during remission state [224, 225]. A small study of 
45 patients with RRMS found a greater risk of clinical relapses and MRI disease 
activity the upcoming year in patients with higher serum leptin levels, suggesting it to 
be a potential biomarker for disease course in MS [226]. MS patients have also been 
reported to have higher levels of leptin in CSF than healthy controls, and this has been 
suggested an essential role for worsening central inflammation in MS [179, 221]. 
Interestingly, leptin deficient mice (ob/ob mice) are resistant for development of EAE, 
but become susceptible to the disease after leptin administration [227]. Endothelial 
leptin receptor knockout mice are also found to have reduced disease burden [228]. 
The leptin receptor expression is upregulated in hippocampus of EAE mice, and the 
endothelial leptin signalling are shown to enhance BBB dysfunction in EAE [228]. 
Serum leptin levels affect EAE as they are found to be increased before the clinical 
onset of EAE in mice, and starvation delayed the disease onset and attenuated the 
symptoms of EAE [229].  
Leptin affects the immune system, and it is suggested that blocking the serum levels of 
leptin may be beneficial for the reduction of autoimmune reactivity [214]. Therapeutic 
leptin antagonism are found effective in preventing and treating immunity-related 
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disorders in mice [230], and could be a possible future treatment for autoimmune 
diseases in humans [230, 231]. 
Adiponectin  
Adiponectin is mainly an anti-inflammatory adipokine. The immune functions include 
suppression of macrophage activity, inducing the production of anti-inflammatory 
cytokines like IL-10, IL-1 receptor antagonist (IL-1RA) by dendritic cells, monocytes 
and macrophages, and suppression of interferon-γ production [211]. This adipokine is, 
however, also found to promote the activation of dendritic cells and to affect the T-
cells towards a pro-inflammatory Th1 and Th17 polarization [211]. In humans the 
serum concentration of adiponectin is about 5-10 mg per ml, much higher compared to 
leptin circulating in concentrations of a few nanograms per ml [211]. The circulating 
levels are affected by several factors like gender, age and lifestyle [211]. Adiponectin 
circulates in three main isoforms, low-molecular weight (LMW) trimers, medium-
molecular-weight (MMW) hexamers, and high molecular-weight (HMW) multimers 
and their biological activity is somewhat different [232]. 
The serum levels of adiponectin in MS patients have been explored with conflicting 
results. A small study found no difference in serum levels between MS patients and 
healthy controls, [233] but several other studies have found decreased levels in both 
adults and children with MS [234-237]. One recent study reported higher serum levels 
in MS patients and an altered oligomerizaton state, with an increase of the high 
molecular weight oligomers [238]. The serum levels of adiponectin is not found to 
increase the risk of MS [239], but some genetic variants of the ADIPOQ genes are 
found to be associatied with susceptibility to PPMS [220]. 
For children with MS, higher serum levels of adiponectin are reported to be associated 
with a lower risk of relapses [235]. However, a recent study of 99 MS patients found 
that patients with higher serum adiponectin levels at baseline had a higher risk of 
disease progression, assessed by multiple sclerosis severity score [238]. Another study 
following MS patients over a 2-year period found no association between adiponectin 
serum levels and disease activity [240].  
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EAE is more aggressive in mice with adiponectin deficiency, causing greater CNS 
inflammation, demyelination and axon injury. The disease load can be enhanced by 
adiponectin treatment [241]. The cause of this effect may be through inhibiting the 
differentiation of Th17-cells, a proinflammatory linage of T- cells related to the 
pathogenesis of most autoimmune diseases [242].  
 
Figure 10. The effect of leptin and adiponectin in innate and adaptive immunity.  
The figure illustrates some of the mechanisms of leptin and adiponectin in immunity. 
Leptin increases the cytotoxic ability of NK-cells, activates neutrophil cells, enhances 
macrophage secretion of proinflammatory cytokines, increases the T-cell 
proliferation and promotes a Th1-cell profile. Adiponectin decreases the phagocytic 
activity of macrophages, lower the expression of HLA II receptors on dendritic cells 
and lower proliferation of T-cells, except for an increase in T-regulatory cells. 
However adiponectin may also increase the activity of macrophages contributing to a 




The role of several adipokines have been explored in MS. Serum levels of visfatin, 
resistin and adipsin are found to be increased in MS patients [236, 240]. A study 
reported of a correlation between plasma levels of adipsin, EDSS score, and MRI 
lesions and suggested a role of adipsin in the accumulation of neurological disability 
[240]. Chemerin works as a chemoattractant for antigen-presenting cells (APC), and is 
shown to be expressed in white-matter lesions of MS. It is involved in the migration of 
peripheral cells into the CNS and may influence the CNS inflammation in MS [244, 
245]. 
 
2.3.2 Inflammation markers 
The chronic CNS inflammation leading to axonal damage and demyelination is a 
distinct pathological characteristic of MS. As the inflammatory process in MS changes 
according to natural fluctuation of the disease, or as a response to treatment, the serum 
levels of different cytokines and interleukins is likely to differ. The levels of 
inflammatory markers may also change in accordance to the interactions of 
environmental factors like smoking, obesity or vitamin D [246]. Since the disease 
course in MS is unpredictable, and few biomarkers are available so far, the search for 
potential candidates is ongoing. Different inflammation markers in serum may be 
possible biomarkers in MS for prediction of disease course and treatment response. 
 
Osteoprotegerin (OPG): Osteoprotegerin is a soluble secreted protein and member of 
the TNF-receptor superfamily. It is important in the regulation of bone metabolism. 
Receptor activator of NF-κB (RANK) is expressed on osteoclasts and needs the binding 
of RANKL for induction of bone resorption [247-249]. OPG can bind to RANKL and 
prevent it from engaging to its receptor RANK, hence inhibit bone resorption. The 
OPG/RANKL/RANK system also play a part in regulation of immune responses, with 
a main function in controlling the number of regulatory T-cells and the formation of 
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self-tolerance in T-cells [247]. Different immune cell subsets express these proteins. 
OPG is expressed in B-cells, RANKL is expressed by active T-cells and macrophages, 
and RANK is expressed by macrophages and dendritic cells [247]. The 
RANKL/RANK/OPG system has a role in MS. A study found that MS patients have 
lower levels of OPG in CSF at disease onset compared to healthy controls [250]. 
Another study found an inverse association between serum levels of OPG and MRI 
disease activity in MS [251]. Interestingly a study showed that mice that lacked 
RANKL in T cells were unable to evolve EAE, suggesting pharmacological RANKL 
inhibition as a potential therapeutic target in MS [252].  
 
Soluble tumor necrosis factor receptor 1 (sTNF-R1): This cytokine receptor is 
characterized by its ability to bind tumor necrosis factor (TNF) and belongs to the TNF-
α receptor superfamily [251]. It modulates immune responses by its ability to bind and 
neutralize the proinflammatory cytokines TNF-α and TNF-β. The serum level of this 
receptor has been explored as a possible biomarker for IFNβ-treatment response in MS 
[253]. A study described that MS patients with a greater increase in the serum level of 
sTNF-R1 had a better MRI response and less clinical relapses, suggesting serum 
measurement as a possible method for identifying the patients most likely to benefit 
mostly of IFNβ-treatment [253].  
 
Chemokine (C-X-C motif) ligand 16 (CXCL16): This small cytokine belongs to the 
CXC chemokine family, and has a role in mediating the innate immune response by 
attracting activated T-cells and NKT-cells. It is expressed on antigen presenting cells 
during inflammation [251, 254]. A study suggested CXCL16 as a possible biomarker 
in MS, demonstrating that the serum levels was inversely associated with MRI activity 
[251]. CXCL16 is important in EAE with a role in the recruitment of inflammatory 
mononuclear cells into the CNS [255].  
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Chemokine (C-C motif) ligand 21 (CCL21): This is a lymphoid cytokine normally 
produced by stroma and endothelium of lymph nodes and spleen [256]. It binds to the 
receptor CCR7, expressed in dendritic cells, T-cells and activated B-cells, and is 
important for the migration of T-cells and dendritic cells to secondary lymphoid organs 
[257]. A study showed that intrathecal production of CCL21 was elevated in MS 
patients, but not in patients with non-MS-type optic neuritis, suggesting that it play a 
role in CNS inflammation [258]. This is consistent with findings in studies of EAE 
indicating that CCL21 play a part in the development of autoimmune inflammation 
[259] and is important for the development of EAE [260]. 
 
Transforming growth factor (TGF) β1: This is a growth factor and multifunctional 
cytokine that is involved in cellular processes like cell growth, apoptosis, cell 
differentiation and extracellular matrix synthesis [261]. It plays a part in CNS 
inflammation, causing activation of microglia, but also possesses immunosuppressive 
properties. A study showed that the administration of TGF-β to mice had a protective 
effect in EAE [262]. Another study found that TGF-β administration enhanced 
remyelination in EAE, and even stimulated human oligodendrocyte maturation 
suggesting a possible therapeutic potential in MS [263].  
 
Pentraxin (PTX3): PTX3 is an acute phase protein that belongs to the group of long 
pentraxins and is produced by macrophages, neutrophils, endothelial cells and dendritic 
cells in response to cytokines like IL-1 and TNF-α [264]. The roles in immunity are 
plentiful including complement regulation, opsonization, removal of apoptotic cells 
and control of neutrophil migration [264]. The serum levels of PTX3 are higher in 
patients with autoimmune diseases than healthy controls [265]. Patients with MS are 
also found to have higher plasma levels, with lower levels during remission than in 
relapse phases [266]. PTX3 seem not to be of major significance during EAE. The 
disease severity was no different in PTX3-deficient mice than wild-type mice, and 
administration of PTX3 did not alter the disease course [267].  
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Matrix metalloproteinase (MMP-9): These enzymes are essential for the degradation 
of various tissue extracellular matrix proteins. They have several roles during 
inflammation, including the regulation of barrier function and activity of inflammatory 
cytokines and chemokines [268].  In MS, MMP-9 are involved in damaging the BBB 
leading to leukocyte extravasation into the brain. An upregulation of MMP-9 is 
associated with a worse disease course in EAE, and mice that lack MMP-9 have proven 
to be less susceptible for the induction of EAE [269, 270]. Serum MMP-9 levels are 
found to be elevated in RRMS patients and found to be related to relapses and MRI 
activity [271, 272]. 
 
Interleukin-1 receptor antagonist (IL-1Ra): IL-1Ra belongs to the IL-1 cytokine 
family and is secreted by immune cells, epithelial cells and adipocytes [273]. Acting 
mainly as a regulation of inflammation through binding and blocking of IL-1 receptors, 
it seems to have a role in terminating the inflammatory response. IL-1RA genes are 
found to be upregulated in MS patients [274]. The anti-inflammatory effects of this 
cytokine are shown to play a part in EAE, whereas administration of IL-1Ra delayed 
the onset of EAE and reduced disease severity in mice [275, 276]. A study showed 
increased serum levels of IL-1Ra in MS patients during IFNβ-treatment, [277] and a 
positive association between vitamin D levels and serum levels of IL-1Ra has also been 
found [278]. 
 
Osteopontin (OPN): OPN is an extracellular matrix protein that is expressed in 
different immune cells like T-cells, dendritic cells, macrophages and natural killer 
cells. The role in inflammatory processes is prominent, causing production of IL-12, 
IL-17 and IFNγ, whereas it inhibits the expression of IL-10. Further, it mediates cell 
migration, adhesion and function as a Th1-cytokine [279]. Several studies have 
explored the potential of OPN as a biomarker in MS. A meta-analysis of 22 studies 
concluded that MS patients have higher levels of OPN in CSF and blood compared to 
controls. Further, patients with active disease had higher levels in CSF compared to 
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patients with stable disease, [280] and also plasma levels are found to be higher during 
relapses [281]. A study found that plasma OPN levels were higher in patients with 
SPMS compared to RRMS patients [281]. This proinflammatory cytokine is important 
in EAE, and OPN-deficient mice are resistant to progressive EAE [282]. 
 
Activated leucocyte cell adhesion molecule (ALCAM): ALCAM belongs to the 
immunoglobulin superfamily and is expressed in epithelial cells, endothelia and 
neurons. It is involved in immune responses where it is responsible for stabilization of 
the immunological synapse, activation and proliferation of T-cells and leukocyte 
migration [283]. This adhesion molecule has been shown to promote B-cell 
extravasation and migration across BBB in MS, and the expression of ALCAM is 
upregulated in both active MS and EAE brain lesions [283]. An increased number of 
B-cells that express this molecule are found in both the serum and the brain of MS 
patients. The blocking of ALCAM causes a less severe EAE disease course, and 
therapeutic antagonism may be a future treatment in MS [284]. 
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3. Study rationale and aims 
 
3.1 Rationale 
Tobacco use and obesity are lifestyle factors known to increase the risk of MS. They 
may also influence the disease course, but studies conducted so far have shown 
conflicting results. Lifestyle factors are modifiable, and knowledge of their role in MS 
can be of great importance, offering patients the opportunity to influence the disease 
by lifestyle choices.  
3.2 Aims 
The aim of this project was to:  
1) Explore the effect of tobacco use in patients with RRMS to determine whether there 
is an association between tobacco use and MRI disease activity, relapse rate and EDSS 
progression. 
 
2) Examine the association between BMI and disease activity in patients with RRMS 
to determine if obesity is associated with a more aggressive MS disease course.  
 
3) Examine if adiponectin and leptin are associated with MRI disease activity in MS, 





4.1 Source of data: The OFAMS study 
 
4.1.1 Study design  
The OFAMS (ω-3 fatty acid treatment in multiple sclerosis) study was a multicenter, 
randomized, double-blind, placebo-controlled trial for investigating whether ω-3 fatty 
acids reduced MRI and clinical disease activity in patients with MS [285]. The study 
population consisted of 92 Norwegian patients with RRMS according to the McDonald 
criteria [286]. Patients were recruited from 13 different neurology departments in 
Norway between December 2004 and July 2006. The inclusion criteria were age 18–
55 years and Expanded Disability Status Scale (EDSS) score ≤5. All patients had active 
disease with ≥1 relapse, or new T1-weighted gadolinium-enhancing (T1Gd+) or T2-
weighted (T2) lesions on MRI in the year prior to inclusion. Patients who used or had 
used any previous immunomodulatory treatment for MS were excluded, as well as 
patients where initiation of medical treatment could not be delayed.  
 
4.1.2 Interventions and follow-up  
Patients were randomized to receive either Triomar™ capsules (Pronova Biocare, 
Sandefjord, Norway) containing 1350 mg of eicosapentaenoic acid (EPA) and 850 mg 
of docosahexaenoic acid (DHA) or placebo (corn oil) at baseline. From month six all 
patients received subcutaneous injections of IFNβ three times weekly. The total follow-
up period was 24 months; six treatment-naïve months (without DMT) and 18 months 
with IFNβ-treatment.  
A total of six patients were lost to follow up, one at baseline, three at study month two, 
one at study month 12 and one at study month 18. Further, five of the patients 
discontinued treatment.  
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The result of the study showed no difference between the group of patients receiving 
omega-3 or corn oil, hence the cohort has later been pooled for several additional 
analyses [73, 89, 251, 278, 287-291].  
The studies in this thesis are all based on the OFAMS study. The varying 86-88 patients 
in the cohort of the three studies had all completed at least 12 months of the OFAMS-
study. Patient characteristics are illustrated in Table 1.  
 
 







Caucasian, n (%) 88 (100.0) 
HLA-DRB1*15-positivea, n (%) 58 (66.7) 
Proportion of T1Gd+ lesions, % (SEM) 52 (5.4) 
Age, median years (range) 39 (19-58) 
Years since diagnosis, median years (range)  1 (0-13) 
Years since first symptom, median (range) 3 (0-23) 
EDSS score at inclusion, median (range) 2.0 (0.0-4.9) 
 
The first paper included 87 of the patients and the second paper included 86 of the patients. 
a) Not available in 4 patients, T1Gd+=Gadolinium enhancing T1 lesions, EDSS=Expanded disability status scale.   
 









All patients were followed with repeated evaluations and measurements during the 
studies as illustrated in Table 3.  
 
 
Table 3: Different examinations and different time points. 
Outcome measures in the studies were combined unique activity, (new MRI T1-Gd 
enhancing lesion, new or enlarging T2-lesion, or both), number of relapses, increased 
disability assessed by EDSS score and NEDA-3-status (no evidence of disease 
activity).  
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Relapse: A relapse was defined as the appearance of new or worsening of old 
neurological symptoms or signs, in the absence of fever, persisting for more than 48 
hours and causing objective changes on neurological examination.  
Disease progression: An increase of ≥1 point in EDSS score recorded at a clinical visit 
and sustained for > 6 months was defined as disease progression. 
MRI: Cerebral MRI was performed according to a standardized protocol comprising 
T2-weighted and T1-weighted gadolinium enhancing (T1Gd+) scan, using a standard 
head coil with a 1,5 Tesla MRI unit. The guidelines for use of MRI in MS trials were 
followed [292]. Blinded assessments of the results were conducted by 2 experienced 
neuroradiologists. The sum of T1Gd+lesions and new or enlarging T2 lesions was 
denoted as combined unique activity (CUA).  
NEDA: Patients with optimal treatment outcome, meaning no disease activity, for the 
follow-up period obtained NEDA-status. NEDA was defined as a composite consisting 
of absence of relapses, no sustained disability progression assessed by EDSS scoring 
and no MRI activity (new T1Gd+ or new/enlarging T2-lesions) for the given period 
[27]. As more demands for an optimal treatment response have evolved, including MRI 
brain atrophy and CSF-findings, the NEDA-status definition used in our studies is 
currently referred to as NEDA-3 status.  
BMI: Height and weight were registered for all patients at inclusion, and BMI was 
calculated as weight/(height)². The patients were categorized based on the WHO 
classification of obesity into three groups; Normal weight patients, (BMI < 25 kg/m²); 
Overweight patients (BMI 25–30 kg/m²); Obese patients (BMI >30 kg/m²). For some 
analyses, overweight- and obese patients were combined into one group. 
Laboratory tests:  The serum samples were collected by venepuncture during the 
planned clinical visits. All were collected at day time between 07-15 p.m, and without 
any special patient preparations. The samples were shipped in a frozen state and stored 
at -80 ºC until post-study analyzes. Some analyses were performed in relation to the 
original OFAMS-study, while others were analysed at later time points as new studies 
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based on the OFAMS cohort evolved. Lab technicians were blinded for any 
information regarding the patients.   
 
-HLA-DRB1 typing:  The HLA-DRB1 status was determined by DNA sequencing. 
Serum was analyzed at the Department of Immunology and Transfusion Medicine, 
Oslo University Hospital, Rikshospitalet, Oslo, Norway with the SeCore DRB1 Locus 
sequencing kit (Invitrogen, Carlsbad, CA, USA). Patients carrying at least one 
DRBI*15 allele were considered HLA-DRB1*15 positive.  
-Neutralizing antibodies against IFNβ (NAb):  NAb were detected with a myoxvirus-
resistant protein A messenger ribonucleic acid induction assay at the Department of 
Neurology, Haukeland University Hospital, Bergen, Norway. Samples with titer >20 
were classified as positive.  
-Inflammation markers: A selection of ten inflammation markers were chosen based 
on knowledge regarding their function in immunity and assumed relevance in MS 
pathogenesis. The serum concentrations were analysed with enzyme immunoassay kits 
(EIA) from R&D Systems (Stillwater, MN, USA) at the Research Institute of Internal 
Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; osteoprotegerin 
(OPG), soluble tumor necrosis factor receptor 1 (sTNFR1), the chemokines CXCL16 
and CCL21, transforming growth factor (TGF)β1, pentraxin 3 (PTX3), matrix 
metalloproteinase 9 (MMP-9), interleukin-1 receptor antagonist (IL-1Ra), osteopontin 
(OPN), and activated leukocyte cell adhesion molecule(ALCAM) [251]. Consecutive 
patient samples were analysed in neighbouring wells on the same plate. The intra-and 
inter-assay coefficient of variation were <10 % for all EIAs.  
-Vitamin D: The 25-hydroxyvitamin D [25(OH) D3 and 25(OH) D2] was measured 
with a radioimmunoassay kit (RIA-kit, ImmunoDiagnostic Systems, Boldon, UK) at 
the Department of Medical Biochemistry, St. Olavs Hospital, Trondheim, Norway. The 
coefficient of variation was 5.4 % and 6.3 % at 29 and 112 nmol/L [89]. 
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-Cotinine: Serum levels of cotinine was measured using liquid chromatography tandem 
mass spectrometry (LCMS) at Bevital AS (Bergen, Norway). All serum samples for 
the same patient were performed simultaneously. The lower limit of detection was 1 
nmol/l, the within-day coefficient of variation was 2.0 - 6.6 % and the between-day CV 
was 3.9 %. 
Cotinine is a nicotine metabolite and the mostly applied biomarker for tobacco use with 
a high sensitivity (96-97 %) and specificity (99-100 %) [293]. The metabolite has a 
half-life of 15-40 hours, reflecting tobacco exposure the last 3-5 days. Serum cotinine 
levels >85 nmol/l is consistent with recent tobacco use, and the cut point mostly used 
for distinguishing tobacco users from non-tobacco users in the general population [293, 
294]. An advantage of cotinine compared to other tobacco-biomarkers is that the 
optimal cut-point is little affected by the prevalence of smoking in the chosen 
population [295]. 
We categorized the patients into tobacco users and non-tobacco users according to 
serum cotinine levels. Patients with serum cotinine level ≥85 nmol/l in ≥60 % of the 
samples were considered tobacco-users. 
 
-Adipokines: Serum-leptin and adiponectin were measured by radioimmunoassay kit 
(Merc Millipore Corporation, Hormonlaboratoriet, OUS, Norway). All samples from 
the same patients were analysed simultaneously, with consecutive samples in 
neighbouring wells on the same plate. The total coefficient of variation for leptin was 
<10%, and for adiponectin <12 %.  
 
4.1.4 Therapy 
The patients in our studies were followed for six months without any DMT, and then 
18 months during interferon-beta-1a (Rebif) treatment. IFNβ was administered as 
subcutaneous injections of 44 μg 3 times per week. The dosage was the same for all 
patients. At the time of the OFAMS study, IFNβ was a primary first-line treatment 
choice for MS. The study design without DMT for 6 months would not have been 
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ethical acceptable today. But at the time when the study was performed, knowledge 
about the importance of early treatment start was limited. In addition, an application to 
the The Norwegian Health Economics Administration for approval of treatment start 
was needed, and the processing time typical 1-4 months. Thus the study design was 
approved by the ethical committee.    
The PRISM study had demonstrated the effectiveness of subcutaneous IFNβ-1a 
treatment in RRMS patients regarding relapse rate, MRI outcomes and disability [296, 
297]. There was also convincing long-term effect, however, in a follow-up study as 
much as 23 % developed persistent neutralizing antibodies and this was associated with 
reduced efficacy [298]. The molecular mechanisms of action for IFNβ are multiple and 
not fully clear. The anti-inflammatory effect of the drug is caused by inhibition of T-
cell proliferation, an altered cytokine response leading to a shift in T-cell subsets from 
a Th1-phenotype towards a more favourable Th2-type, and reduced T-cell migration 
[11]. The lymphocyte migration through the BBB is decreased by alterations in cellular 
adhesion molecule expression and decreased matrix metalloproteinases. Further, there 
is an enhancement of anti-inflammatory cytokines, and the expression of HLA II 
molecules are decreased causing less activation of lymphocytes [299]. As more 
efficient DMTs for MS have evolved and become available, IFNβ is no longer a 
common choice of therapy in Norway, but may still be considered in some cases [3].  
Several factors may interfere with the efficacy of IFNβ-treatment including 
noncompliance and development of antibodies [300]. The development of antibodies 
is a common phenomenon for biological medications. Several patients develop binding 
antibodies (BAbs), and a smaller proportion of patients develop neutralizing antibodies 
(NAbs) that interfere with the biological and therapeutic effect of the drug. The 
immunogenic potential of IFNβ varies from 28-47 %, and is independent of gender, 
age and disease duration [301, 302]. For most patients the evolvement of NAbs will 
occur during the first 18 months of therapy, and analyzing for NAbs during IFNβ-
treatment is recommended in an European guideline [302]. Obese patients have been 
shown to have a decreased ability to produce IFN-α and IFN-β in response to viral 
infections, and this is caused by an increased SOCS3 basal mRNA expression in 
peripheral blood mononuclear cells, a protein that negatively regulates type I 
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interferons [303]. This could possibly present a cause for a poorer response to IFNβ-
treatment in obese. However, a study did not find that the expression of this protein 
was different between responders and non-responders to IFNβ [304].  
The IFNβ serum level can be quantified by an ELISA method, but therapeutic drug 
monitoring for assessing the individuals drug concentration in relation to therapeutic 
response is not used for IFNβ-treatment as the drug has a short serum half-life [305]. 
However, for some patients the biological activity of IFNβ can be assessed by 
evaluating different IFN-stimulated genes such as myxovirus-resistance protein A 
(McA), b2-microglobulin and oligo-adenylate-synthetase. Especially measurement of 
McA and NAbs are shown to help predicting the risk of new relapses [306]. An 
evaluation of the therapeutic response based on both biological, clinical and MRI 
follow-up is advised for an early detection of non-responders [307]. However, 
measurement of the IFNβ biological activity by McA quantification is mostly used in 
clinically challenging cases as the test is not available in most laboratories [302]. 
 
4.1.5 Ethical approval and patient consent 
The OFAMS study protocol was approved by the Regional Committee for Medical and 
Health Research Ethics in Western Norway and the Norwegian Medicines Agency. 
The study was undertaken in accordance with the Declaration of Helsinki and the 
European Medicines Agency Note for Guidance on Good Clinical Practice. All patients 




This study included 87 of the original 92 OFAMS patients. A total of nine MRI scans 
(one during study months 1-6 and eight during study months 7-24) were missing. Seven 
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blood samples for serum-cotinine analysis were missing for months 0-6 and 39 for 
months 7-24.  
The association between tobacco use and MRI activity was assessed by a logistic 
regression model for hierarchical data, for the total study period, the six months prior 
to treatment and the 18 months with IFNβ-treatment. All analyses were adjusted for 
gender, age, BMI and HLA-DRB1*15 status. The differences in number of relapses 
and baseline EDSS scores among tobacco-users and non-tobacco users were assessed 
by Independent samples t-test. 
Paper II  
This study included 86 of the original 92 OFAMS patients. A total of nine MRI scans 
(one during study months 1-6 and eight during study months 7-24) were missing. The 
association between BMI and MRI activity before and during IFNβ-treatment was 
assessed by logistic regression model for hierarchical data. The association between 
BMI and inflammation markers was estimated by a linear mixed model with random 
effects for patients and fixed effects for BMI. The results were reported as regression 
coefficients. Log–transformed inflammation marker values were employed in the 
models since most values were not normally distributed. The association between 
seasonally adjusted vitamin D status and BMI was assessed by estimating a linear 
mixed model with random effects for patients and fixed effects for vitamin D. 
Explorative analyses of MRI activity within different categories of BMI status as well 
as NEDA-status were assessed by z-test for proportions and independent samples t-
test. For multiple comparisons, one-way analysis of variance (ANOVA), followed by 
Fishers’ least significant difference method was used. All analyses was adjusted for 
age and HLA-DRB1*15 status. 
Paper III 
This study included 88 of the original 92 OFAMS patients. A total of nine MRI scans 
(one during study months 1-6 and eight during study months 7-24) were missing. Six 
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blood samples for serum leptin and adiponectin were missing for months 0-6 and 22-
24 blood samples for months 7-24 (24 for leptin).  
The inter- and intra-patient variance was estimated by a linear mixed model (LMM) 
with random intercepts for patients. Mean serum levels before and during treatment 
were compared by including fixed effects for period into LMM. The associations 
between baseline levels of adipokines and BMI, relapses, NEDA and EDSS score were 
assessed by linear regression. 
Generalized linear mixed models with random intercepts for patients were used to 
estimate the association between MRI activity and adipokines. Associations between 
time profile in adipokines, NEDA-status, EDSS progression at baseline and relapses 
were estimated by LMM. All models were adjusted for gender, age and BMI.  
For all analyses results with p values <0.05 were considered statistically significant.  
The analyses for all papers were performed in SAS v 9.4 and SPSS v 22 or 25. 
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5. Summary of results 
 
5.1 “No association of tobacco use and disease activity in 
multiple sclerosis”.  
Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI,  Wergeland S, Beiske 
AG , Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen 
O. Neurol Neuroimmunol Neuroinflamm, 2016;3:e260.  
 
The aim of the study was to explore the effect of tobacco use for disease activity in 
MS. A cohort of 87 RRMS patients originally included in a randomized placebo-
controlled trial of omega-3 fatty acids in MS were followed for two years, 6 months 
before and 18 months during IFNβ-treatment with repeated MRI examinations, clinical 
evaluations and collection of serum samples. Cotinine, a serum biomarker of tobacco 
use was measured at five different time points. The association between tobacco use 
and MRI activity was assessed by logistic regression.  
There was no association between tobacco use assessed by cotinine level and MRI 
disease activity. We found that 53 (61 %) of the 87 patients had cotinine levels ≥ 85 
nmol/l in ≥60% of the measurements and were classified as tobacco users. For these 
patients there were no association between cotinine levels and MRI activity during the 
follow-up period, i.e. there were no difference in MRI activity between patients likely 
to be heavy smokers and light smokers. The results were consistent for the six 
treatment-naïve months (receiving only -3 fatty acids or placebo) and the 18 months 
during IFNβ-treatment. There was no difference between tobacco users and non-
tobacco users in mean baseline EDSS score or EDSS progression during follow-up. 
The number of patients with clinical relapses in the study period did not differ between 
tobacco users and non-tobacco users. Adjustment for gender, age, BMI and HLA-
DRB1*15 status did not change our results. 
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5.2 “Body mass index influence interferon-beta treatment 
response in multiple sclerosis”. 
Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve 
KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust 
P, Ueland T, Sagen JV, Torkildsen Ø.J Neuroimmunol. 2015; 288:92-7.  
 
The aim of this study was to explore the association between BMI and disease activity 
in MS. A cohort of 86 RRMS patients originally included in the OFAMS trial were 
followed for two years, 6 months before and 18 months during IFNβ-treatment. The 
follow-up included repeated MRI examinations, clinical evaluations with EDSS score 
and serum samples. Height and weight were measured at baseline and the patients were 
categorized according to WHO classification as normal weight patients (BMI < 25 
kg/m²), overweight patients (BMI 25–30 kg/m²) and obese patients (BMI >30 kg/m²). 
The serum samples were analyzed for vitamin D and 10 different inflammation markers 
at baseline and after 1, 3, 6, 7, 9, 12, 18 and 24 months. The association between BMI 
and MRI activity was assessed by logistic regression and by independent samples t-
test. The association between BMI and inflammation markers and vitamin D was 
assessed by estimating a linear mixed model.  
The mean BMI in the cohort was 25.7 kg/m2 and the cohort consisted of 46 normal 
weight, 23 overweight and 17 obese patients. Of the patients with normal weight, 24 
patients (52 %) had no MRI activity (CUA) during IFNβ- treatment compared to 8 (20 
%) of the combined overweight and obese patient-groups. Combining no MRI activity, 
no clinical relapses and no EDSS progression, 26 % of the patients with normal weight 
obtained NEDA-3 status during the treatment period compared to only 13 % of the 
overweight and obese patients. There was no association between BMI and MRI 
activity for the 6 months prior to IFNβ-treatment and this was consistent after 
adjustment for gender, age and HLA-DRB1*15 status.  
We found a positive correlation with serum IL-1Ra and an inverse correlation with 
PTX3, but no correlation between BMI and seasonally adjusted vitamin D levels.  
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5.3 “Serum levels of leptin and adiponectin are not 
associated with disease activity or treatment response in 
multiple sclerosis”.  
Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve 
KS, Hovdal H, Midgard R, Sagen JV, Torkildsen Ø. J Neuroimmunol. 2018;323:73-
77.  
The aim of this study was to examine the association between serum levels of two 
adipokines (leptin and adiponectin) and MRI disease activity in MS. A cohort of 88 
RRMS patients originally included in a randomized placebo-controlled trial of omega-
3 fatty acids in MS (the OFAMS study) were followed for two years, 6 months prior to 
and 18 months during IFNβ-treatment, with repeated MRI examinations, clinical 
evaluations and serum measurements of adipokines. The association between serum 
levels of adipokines and MRI activity was assessed by logistic regression analyses.  
There was no association between the serum levels of leptin or adiponectin and MS 
disease activity. We found a great inter-individual variation in the serum levels of leptin 
and adiponectin, but the levels were remarkable stable for each patient throughout the 
study period. The minimum serum-leptin level was 50 pmol/l and the maximum was 
6250 pmol/l. The minimum serum-adiponectin level was 0.8 mg/l and the maximum 
was 31.8 mg/l. About 90 % of the total variation in serum levels was caused by 
between-patients variations.  
We observed no association between serum leptin or adiponectin level at baseline and 
EDSS score. Patients with relapses or EDSS progression did not differ in serum levels 
of leptin or adiponectin at baseline or during the study period compared to patients 
without new disease activity.  
Further, there was no difference in the serum levels of adipokines between the patients 
that obtained NEDA-3 status and patients that had disease activity. The serum leptin 
level was higher and serum adiponectin level lower before than during IFNβ-treatment 




6.1 The contribution of the findings 
The exact pathogenesis of MS is not known, but the disease is most likely induced by 
a complex interplay of genetic and environmental factors affecting the immune system. 
Obesity and smoking both possess a number of different pathogenetic mechanisms 
promoting inflammation and possibly driving the immune response towards 
autoimmunity. Both are established risk factors for MS, and they have also been 
associated with MS disease course. However, little is known of how obesity and 
tobacco use may effect the MS disease activity. The papers in this thesis provide more 
information on these questions. 
The MS disease course is unpredictable, and the severity of the disease varies greatly 
between patients. So far, there are no available biomarkers distinguishing patients 
regarding prognosis and preferred treatment choice, and the search for biomarker 
candidates is thus ongoing. The last study in this thesis explored the potential of two 
adipokines as biomarkers for IFNβ-treatment response in MS.  
 
Smoking and MS disease activity 
Although smoking is one of the most studied environmental factors in MS, few studies 
had addressed the effect of tobacco use on MS disease activity at the time of our study. 
The need for more knowledge was evident. Two previous studies did not find any 
association between smoking and relapse rate in MS [119, 128], and a third study 
reporting of no association between MRI activity in MS and serum cotinine levels had 
recently been published [125]. In line with these results, we did not find any association 
between MS disease activity and tobacco use.   
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Later, a large Danish study of 834 RRMS patients has been published, reporting 20 % 
increase in relapse rate for smoking RRMS patients during IFNβ-treatment. The risk 
was dose dependent, and each pack of cigarettes per day increased the number of 
relapses by about 27 % [129]. The same Danish study group also recently reported of 
an increase in relapse rate in MS patients who smoked during natalizumab treatment 
[127]. The results of these studies differ from our findings, and several factors may 
contribute to this discrepancy. The first study was questionnaire-based, and the patients 
classified their smoking behaviour as “occasional smoking” or “regularly smoking”. 
The term “regularly smoking” was not explicitly defined. As smoking is considered a 
“bad habit”, it is likely that the patients had a tendency to underreport their own 
smoking behaviour, and that some smokers are misclassified as non-smokers. This 
assumption is supported by the fact that only 29 % of the patients in this study were 
smokers compared to 61 % in our study, although it is most likely that Norwegian and 
Danish MS patients have somewhat similar smoking habits. It is possible that the 
patients classified as smokers in their cohort was mainly heavy smokers, whereas the 
smokers in our cohort probably consisted of both light smokers and heavy smokers. In 
our study, the patients were classified according to serum cotinine levels, and it is 
possible that some of the patients used oral tobacco and were misclassified as smokers. 
This could affect the results as oral tobacco has been reported of a possible protective 
effect in MS [44]. However, the use of oral tobacco was small in Norway at the time 
of this study constituting below 20 % of the total proportion of tobacco consumption, 
and it is therefore likely that the cotinine levels in our samples mainly reflect smoking 
[308]. The different results may also be caused by the number of study patients. It is 
possible that the large Danish study observed a difference that we did not detect due to 
a small cohort and thus a greater possibility of type II error.   
In the second Danish study, the patients had a very active RRMS disease with a mean 
of one relapse a year, contrary to our cohort with relatively few relapses overall. Thus, 
our cohort consists of RRMS patients with a more moderate disease activity. For MS 
patients with a more aggravated disease and a larger inflammatory component, 
smoking may have a larger influence on the relapse rate.  
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An association between tobacco use and MS disease activity would fit well with the 
knowledge that smoking likely affects disease progression in MS [115, 120, 122]. 
However, the effect on disease progression may also be mediated through other 
mechanisms since studies have shown more brain atrophy and higher levels of serum 
neurofilament in smoking MS patients [131, 136]. To conclude, the results on this topic 
are conflicting, and there is a need for more studies regarding smoking and disease 
activity in MS. Larger prospective studies involving both questionnaires regarding 
smoking behaviour and the use of other nicotine products, and cotinine analyses could 




N Design Follow 
up 
time 
Conclusion Limitations Ref 
Pittas et 
al, 2009 
N=198  Prospective Median 
2,5 
years 
Smoking was not 
associated with 
relapse rate. 






1 year No difference in 12-
month self-reported 
doctor-diagnosed 
relapse rate according 
to smoking status. 








5 years Smoking (assessed 
by serum cotinine) 
was not associated 
with relapse rate. 
-Smoking assessed by 
serum cotinine levels,-
possible misclassifications 








2 years Smoking (assessed 
by serum cotinine) 
was not associated 
with relapse rate. 
-Small cohort 















Higher relapse rate in 
smokers vs. non-
smokers, Incidence 
rate ratio: 1.20 
(p=0.027). IRR 
increase of 27 % per 
pack of cigarettes per 
day.  
-Recall bias 
-Vague definition of 












2 years Higher relapse rate in 
smokers vs. non-
smokers. Smoking 
one pack of cigarettes 
per day ass. with 38 
% increased relapse 
rate.  
-Recall bias  
-Vague definition of 







Table 4: Studies exploring smoking and disease activity in MS. 
 
Smoking and MS disease progression 
Several reports have found an effect of smoking on lesion load and brain atrophy on 
MRI [120, 131]. Further, several studies have reported of an association between 
smoking and EDSS progression prior to and after our publication [115, 120, 309, 310]. 
In our study, there was a non-significant trend of disease progression in smokers, where 
37 % of the tobacco users had EDSS-progression compared to 21 % of the non-tobacco 
users. We had a relative short follow-up period of only 24 months and it is possible 
that our results could have been different with a longer follow-up time. Further, we had 
a relatively small cohort with overall small changes in EDSS score, and the findings 
could have been different in a larger cohort or if patients with a more severe MS had 
been included. 
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Obesity and MS disease activity 
We found no association between BMI and disease activity for the treatment-naïve 
period. Obesity causes a systemic low grade inflammation and may influence 
autoimmune diseases in a number of ways [155]. However, there are few reports on 
how obesity may affect MS disease activity. An American study explored the effect of 
comorbidities in MS and found that obese women had a more relapsing disease course 
at onset [175], and a recent report found a trend of higher annual relapse rate in obese 
MS children [177]. In a study of pediatric-onset MS there was no association between 
BMI at the time of diagnosis and disease activity [311], and a prospective study of 141 
RRMS patients found no association between BMI and the risk of relapses [176]. These 
latter reports are in coherence with our results. So far, no other studies have explored 
the association between BMI and MRI disease activity.  
Obesity has the last decades been established as a risk factor for MS, based on multiple 
studies reporting an association between obesity in youth and MS risk [162-164, 167, 
172]. The pathogenetic mechanisms are not known, but it is hypothesized that different 
ways of influencing the immune system are involved. Since obesity affects the MS risk, 
it is likely that similar immune mechanisms also play a role for the disease activity and 
evolvement. In our cohort there were relatively few relapses and the number of patients 
that were overweight and obese were relatively small, and therefore our results cannot 
exclude a possible association.  
There is a need for further studies exploring the association of obesity for MS disease 
activity, preferably in a larger cohort with a higher proportion of obese patients. Our 
cohort is probably most representable for patients with a moderate severe RRMS, and 
the possibility of an association should also be explored in a cohort of MS patients with 





Obesity and IFNβ-treatment response  
We found that fewer overweight or obese patients attained a NEDA-3 status compared 
to patients with normal weight. Potential explanations could be that the low-grade 
inflammation observed in obesity may cause a more potent disease or a suboptimal 
treatment response. There could also be differences related to the administration and 
dosage regime of the IFNβ-treatment. To examine the possibility of a more potent 
disease, caused by inflammatory mechanisms, we checked for an association with ten 
serum inflammation markers that had previously been analysed in this cohort [251]. 
The serum levels of the inflammation markers were not different among the overweight 
and obese patients and could not explain our results. We also performed another 
analyses to explore the serum levels of two adipokines in the cohort. The results of this 
study showed no association between the adipokines and MS disease activity. There 
was no difference in the serum level of leptin or adiponectin between the patients that 
obtained NEDA-status and the patients with disease activity, suggesting that the result 
of our primary study reflects a suboptimal IFNβ-treatment response in obese patients. 
For routine IFNβ-treatment, all patients receive the same dose independent of their 
BMI. Most studies of IFNβ-treatment have not addressed BMI as a treatment-related 
factor [312-314], but different doses of IFNβ-treatment has been explored in some 
studies, with conflicting results. However, none of these studies adjusted for BMI [297, 
315]. So far, only one study has explored the effect of BMI in IFNβ-treatment, but 
since the patients had SPMS there was no effect of IFNβ-treatment overall [316].  
Obesity affects drug pharmacokinetics and bioavailability, but knowledge of the effect 
for subcutaneous injections is scarce [317]. However, some studies describe lower drug 
concentration after subcutaneous injection in obese patients [318-320]. Obese patients 
have a decreased subcutaneous blood flow as a result of a decrease in capillary density 
in subcutaneous tissue that may cause a suboptimal drug absorption [321]. The lower 
drug concentration may also be explained by the fact that obese patients have a larger 
distribution volume [321]. Other factors that can lead to less biological effect of IFNβ 
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include noncompliance and Nabs. The development of NAbs did not differ between 
normal weight patients and obese patients in our cohort.  
After our publications, two reports have found a suboptimal treatment response in 
obese MS patients. In 2019, a large report described that obese children with MS 
experienced almost twice as many relapses during treatment with IFNβ and glatiramer 
acetat, and that the switch rate to a second-line DMT was about 50 % higher in obese 
than normal-weight children [165]. Another report of pediatric MS patients which 
compared patients from the US and seven other countries, showed that the patients 
from US had higher BMI, more frequent relapses during IFNβ-treatment and more 
often switched to another DMT [322]. 
All DMTs except cladribine are administered as the same dosage for all patients 
regardless of BMI. Few studies have explored the role of BMI for these treatments 
[323]. A recent study found that high BMI was associated with a lower natalizumab 
receptor occupancy on leukocytes and wearing-off symptoms during natalizumab 
treatment [324].  
All together, these papers emphasize the need for investigating the role of obesity for 
pharmacokinetics in IFNβ-treatment and also other DMTs, and that there most likely 
should be BMI-adjusted dosing regimens. Another option would be to strive for a 
closer evaluation of bioactivity of the drugs, possible by the biomarker for monitoring 
IFNβ-treated patients, -MxA mRNA [306]. 
 
Obesity and inflammation markers 
Obesity causes a low-grade systemic inflammation. We studied the association 
between BMI and 10 different inflammation markers, and found that two of the 
markers were associated with BMI. Pentraxin-3 (PTX3) is an inflammatory protein 
with several immunological functions. PTX3 serum levels reflect the grade of 
inflammation and tissue damage, and has been suggested as a biomarker in 
autoimmune diseases. In our study we found that PTX3 was inversely associated with 
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BMI, a finding in coherence with another report [325]. A study have described plasma 
PTX3 levels of MS patients to be higher during relapses [266]. Moreover, some studies 
indicate that PTX3 has no major role in the neuroinflammation of MS [267, 326]. Bases 
on our results, any association between obesity and MS activity does not seem to 
involve PTX3-mechanisms.  
Interleukin 1 receptor antagonist (IL1-Ra) is a soluble inhibitor of the proinflammatory 
cytokines IL1-α and IL1-β, known to play a role in MS and EAE [327]. Administration 
of IL-1Ra are shown to have a protective effect in EAE contributing to a milder disease 
course, [276] and serum levels of IL-1Ra correlate with disease activity and treatment 
in MS [328, 329]. We found a positive correlation between the serum level of IL-1Ra 
and BMI, in coherence with other studies [330, 331]. Since higher levels of IL-1Ra are 
found to be beneficial in MS, our results suggest that any negative influence of obesity 
for MS is not caused by IL-1Ra related mechanisms.  
 
Obesity and vitamin D 
We did not find any correlation between serum 25-hydroxyvitamin D and BMI. This 
finding is somewhat unexpected since vitamin D is a fat soluble vitamin that can be 
sequestered in the fatty tissue, causing lower serum vitamin D levels [332, 333]. Other 
mechanisms for lower vitamin D levels in obese are less sun exposure and volumetric 
dilution [333]. The association of low serum 25(OH)D level with obesity have been 
found in studies of both adults and children, and serum 25(OH)D level is reported to 
be 20 % lower in obese that normal weight individuals [169, 170, 332-334]. However, 
there are also studies of no correlation [335, 336]. Most studies reporting of a 
correlation consist of a high proportion of patients with BMI >30. Our cohort had 
relatively few obese patients, and it is possible that our findings would have been 




Adipokines and MS disease activity 
In our cohort, fewer of the overweight and obese patients obtained NEDA-status. We 
sought to further explore on this finding in the last paper of this thesis, checking 
whether there could be a more profound inflammation and different levels of 
adipokines in the obese patients. Leptin and adiponectin are fatty hormones with 
important roles in the regulation of the immune system, contributing to the obesity 
driven systemic inflammation. Most studies have found increased serum leptin levels 
and decreased adiponectin levels in MS patients compared to healthy controls, and it is 
therefore assumed that they somehow affect the MS disease [218, 236]. But studies 
regarding their role in MS disease activity are conflicting [223-226, 238, 240]. These 
adipokines are found to possess important effects in EAE, as leptin deficient mice are 
resistant for developing EAE, and adiponectin administration improve the EAE disease 
severity [227, 241]. Based on the effect of leptin in EAE animal models, therapies for 
limiting the bioavailability of leptin has been suggested [337]. In our study, however, 
there was no association between MS disease activity and the serum level of these 
adipokines. The serum levels did not differ for patients with higher EDSS score at 
baseline or between patients that did or did not obtain NEDA-status. Our study suggests 
that these adipokines do not have profound roles associated with MS disease activity, 
and indicates that the therapeutic potential of medications influencing serum level of 
these adipokines is most likely poor.  
 
Adipokines as biomarkers 
Leptin and adiponectin are suggested biomarkers in MS, and a number of studies have 
explored the serum fluctuations in MS, with largely heterogenous results. For serum 
leptin, higher levels initially were found to predict a more aggravated disease the 
upcoming year, but in another report high levels initially were associated with a milder 
disease, while other studies have found that the levels were higher during remission 
state [224-226, 235]. For adiponectin, higher serum levels in children with MS are 
found to be associated with a lower risk of relapses, but another study found opposite 
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results where higher baseline levels were associated with disease progression [235, 
238]. Yet another study found no association between serum adiponectin levels and 
MS disease activity [240].   
We did not find any association between relapses or MRI disease activity and the serum 
levels of leptin or adiponectin. Further, the serum levels did not differ among patients 
with or without EDSS-progression or for patients that did or did not obtain NEDA-
status. However, during IFNβ-treatment the serum leptin levels dropped and the 
adiponectin levels increased for all patients reflecting the anti-inflammatory effect of 
the drug.  
For both leptin and adiponectin there were major differences in the serum levels 
between patients, but the levels for each patient were relatively stable for all eight 
measurements during follow up. About 90 % of the total variation in serum levels of 
the adipokines could be attributed to between-patient variations. According to these 
results, one could presume that if the serum levels of these adipokines had a role in the 
disease activity or course, it would be highly detectable in this cohort given the large 
differences between patients. Our results indicate that neither of these adipokines have 
potential as biomarkers for disease activity or IFNβ-treatment response in MS.  
 
Conclusions 
In this thesis we explored the role of tobacco use and obesity in MS. After our studies 
were conducted, more reports have been published on this topic. Smoking and BMI 
have independently been shown to be negatively associated with global disability and 
depression in MS [338]. Both factors together have also shown an even worse 
prognosis, and obese MS patients that smoked had an increased risk of SPMS [339].  
Smoking and obesity are modifiable lifestyle factors, opposed to other fixed factors 
affecting the disease course, such as genetics. The effect of lifestyle changes can make 
a great impact on the disease. A study showed that patients who stopped smoking 
before or after the disease onset had the same disease progression as never smokers 
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[115]. It has also been demonstrated that patients who stopped smoking at the time of 
the diagnosis developed SPMS eight years later than the patients that continued to 
smoke [340]. There is a need of more studies to gain information on lifestyle factors, 
to guide patients and remind healthcare providers to engage and motivate for lifestyle-
based behaviour changes [341]. The papers in this thesis all contribute with information 
and may cause more focus on the field.  
 
6.2 Methodological considerations and limitations 
 
6.2.1 Patient population 
 
The OFAMS cohort is a well-defined cohort with a thoroughly follow-up over two 
years. It comprised 92 RRMS patients with a mean age of 39 years and a female: male 
ratio of about 2:1. All patients had active disease with ≥1 relapse or new T1-weighted 
gadolinium-enhancing (T1Gd+) or T2-weighted (T2) lesions on MRI in the year prior 
to inclusion. Although the patients had an active MS disease, they were followed for 
six months without DMT. At the time this study was conducted it was not unusual to 
wait some months before starting treatment and the study had ethical approval, but this 
kind of treatment delay would probably not be permitted in a study nowadays. Patients 
that demanded immediate disease modifying treatment were, however, excluded from 
the study. This suggests that our results may be generalized to RRMS patients with 
moderately active disease.  
The number of relapses in this cohort was relatively low, especially for the period 
during IFNβ-treatment, meaning it could be difficult to detect possible associations 
between some factors and relapses. In our studies we have been aware of this weakness, 
and although we have checked for an association with relapses, our main assessment 
has been MRI disease activity.   
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A total of 26 of the patients had an EDSS progression during the study period. Although 
EDSS score is an established measure to evaluate disease progression and treatment 
response, it is not very sensitive for smaller changes early in the disease course. For 
our results regarding disease progression, the follow-up period is probably too short. 
As an example, smoking has been shown to affect disease progression in several 
studies, but we were not able to find this in our study, although we found a non-
significant trend. This might have been due to short follow-up time.  
Our studies consisted of 86-88 RRMS patients. The small population size is a weakness 
increasing the likelihood for type II error, i.e. falsely acceptance of a null hypothesis 
of no association when there actual is an association.   
 
The patients had multiple MRI examinations, but brain atrophy was not examined. 
Studies have shown an association between brain atrophy and both smoking and 
obesity [131, 185]. It is possible that increased brain atrophy due to neurodegeneration 
is the cause of increased disease progression in smoking MS patients, and not a more 
active inflammatory disease. This theory would fit well with our results, hence to 
examine MRI brain atrophy and possibly also analyzing serum neurofilament as an 
assessment of neuroaxonal injury would have been interesting and could have 
strengthen our results.  
The original study was a randomized controlled study, a strength regarding the patient 
inclusion and stringent data collection. However, it is a weakness that all studies in this 
thesis were not original studies assembled according to a hypothesis, but retrospective 
studies based on data from the first study. This implicates that measurements and data 
are not optimally collected for our study purposes. For our study on tobacco use we 
classified the patients according to serum cotinine levels as the patients were not asked 
about smoking habits in the original OFAMS-study.  
The patient cohort from the OFAMS study has been the objective of a number of 
studies, searching for different associations with MS disease activity. So far, studies 
have been published on vitamin A, D, E, different inflammation markers, α-linolenic 
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acid and EBV- antibodies in addition to the studies included in this thesis [73, 89, 251, 
278, 287-291]. For this material a large number of tests have been carried out without 
pre-planned hypothesis and there may be a possibility for type 1-errors, hence finding 
a false association. In our second study we explored the association between BMI and 
ten different inflammation markers, and for PTX3 and IL1-Ra the association would 
still have been significant after bonferroni correction.  
 
6.2.2. Confounders 
We adjusted for HLA-DRB1*15 status and gender in our studies. HLA-DRB1*15 is 
the major risk allele for MS, and is reported to interact with both smoking and obesity, 
greatly increasing the risk of the disease [63, 64]. As for most autoimmune diseases, 
the prevalence of MS is greater among women. There might be gender differences in 
the disease caused by effect of gonadal hormones on the immune system, and 
differences in response to immunotherapy [10].   
We did not adjust for NAbs in these studies. However, 27 of the 88 patients developed 
NAbs during IFNβ-treatment. This is a confounder that could potentially affect our 
results, and it is a weakness that this was not adjusted for and discussed in our reports. 
However, we have re-analysed our main results adjusting for NAbs. This did not alter 
any of our results. In the second paper, we found that 19 of the normal weight patients, 
8 of the overweight patients and no obese patients had NAbs. Interestingly, four of the 
patients obtaining NEDA-status had NAbs; three normal weight patients and one 
overweight patient. Thus NAbs did not explain the difference in NEDA-status between 
normal weight patients and overweight-and obese patients.  
Serum vitamin D level was not adjusted for in any of our studies, even though an 
association between serum vitamin D levels and MRI-activity has been confirmed in 
this cohort [89]. The serum levels of 25(OH) D are found to be reduced in smokers, 
and passive smoking is also associated with lower vitamin D levels [342, 343]. Obese 
individuals tend to have lower vitamin D levels than individuals with normal weight. 
 71 
In our second study we therefore explored the correlation between BMI and serum 
vitamin D level in this cohort, but the correlation was weak.  
Another potential confounding factor in our study is dietary habits. A typical “Western 
diet” with much saturated fatty acids may cause a proinflammatory effect on the 
immune system and also affect BMI. For this cohort we had no information regarding 
dietary behaviour.  
Serum cholesterol profile are reported to be associated with the MS disease course 
[176, 181, 182]. Further, the lipid profile and function are found to be altered in MS, 
with a more profound effect in patients with low BMI, possibly contributing to disease 
progression [344]. Hence, this may have been a confounding factor in our BMI study. 
A recent study describes changes in serum cholesterol in relation to IFNβ-treatment, 
and a greater decrease in HDL cholesterol was associated with less long-time brain 
atrophy, suggesting it to be a biomarker for treatment response in MS [345]. The 
measurement of serum cholesterol levels and adjusting for this in our cohort could have 
been an interesting supplement analysis, possibly strengthening our results.  
Physical activity has a role in MS, as excessive physical activity has been shown to 
decrease the MS risk regardless of BMI [45]. For children with MS, more physical 
activity was associated with a lower annual relapse rate [346]. We had no information 
about the grade of physical activity for the individual patients in our cohort, and this 
may be a possible confounder for our results.   
Body composition and fat distribution may have been a confounding factor in our BMI 
studies. High weight may in some cases reflect high muscle mass, and it is the amount 
of fat tissue that is likely to affect the low grade systemic inflammation that could be 
the connection between obesity and MS. In our study it could have been a strength to 
add measure of waist circumference and body composition, presumably by bio-
impedance measurement or dual energy X-ray absorptiometry, in addition to height 
and weight.  
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6.2.2 Serum analysis and laboratory testing 
All studies are based on analyses of blood samples, collected in the original OFAMS- 
study. Samples were collected in different treatment centers and transported in a frozen 
condition to Haukeland University hospital for cryopreservation. The samples were 
stored at -80°C until analysis. The analyses were performed simultaneously for all 
samples from each patient. The lab technicians were blinded for treatment, as well as 
MRI activity. However, there are a risk of pre-analytic, analytic and post-analytic 
variations and errors.  
Furthermore, the samples were not originally collected for the tests of cotinine and 
adipokines. The serum leptin levels have a high grade of diurnal variation, and 
optimally all samples should have been collected at the same time of the day. Since all 
the samples in the study were collected at daytime between 07.00-15.00 p.m, this is 
probably not a great limitation in our study. 
For adiponectin we did not analyze the different isoforms. Since they possess some 
different biological effects, it might have been interesting to check for the association 
of the different isoforms with MS disease activity.  
Cotinine is a nicotine metabolite that reflects the tobacco use the last 3-5 days. The fact 
that we used this biomarker and not patient questionnaires to classify tobacco users is 
a weakness. Patients that may have smoked regularly, but recently quit will according 
to our method be classified as non-tobacco users, even though cigarette smoking may 
have long-lasting consequences on the immune system. If so, it might have affected 
our results. Then again, questionnaires also possess weaknesses, and since smoking is 
known to be a bad habit, people tend to underreport the actual amount. A combination 
of self-reported data validated by serum cotinine measurements would have been the 
optimal solution.  
The use of snuff and other nicotine products may have been confounders in our tobacco 
study as nicotine is shown to have a protective effect in inflammatory diseases by 
dampening inflammation. If some of the patients had high serum cotinine level because 
of the use of snuff this could have affected our results. At the time of our study the 
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proportion of smokeless tobacco consumption in Norway was low, and we therefore 
assume that the cotinine levels predominantly reflect smoking [347].  
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7. Conclusions 
Paper I: We did not find any association between serum cotinine level and MRI 
disease activity. Our results indicate that tobacco use do not influence short-term MS 
disease activity.  
 
Paper II: Fewer of the overweight and obese patients in our study obtained NEDA-3 
status after the 18 months of IFNβ-treatment compared to the normal weight patients, 
suggesting that BMI may affect IFNβ-treatment response. This indicates that the 
treatment should be individualized according to weight, opposed to the standard 
treatment regime of one dose for all.  
 
Paper III: We did not find any association between the adipokines leptin and 
adiponectin and clinical- and MRI disease activity, indicating that these adipokines are 
not suitable as biomarkers for disease activity in RRMS.  
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8. Further perspectives 
Several studies have contributed to a greater understanding of the relationship between 
environmental and lifestyle factors, and MS. Even though the cause of MS is still 
unknown, strong evidence supports an involvement of both genetic and environmental 
factors. Low serum vitamin D levels, smoking and obesity likely increase the risk of 
MS and may also effect the disease course. Interestingly, these factors are all 
modifiable. Relatives of MS patients can influence their MS risk by striving for a 
normal body weight, avoiding or quit smoking and by taking vitamin D supplements. 
For MS patients, vitamin D supplementation and smoking cessation are recommended. 
In this thesis, we have contributed with knowledge regarding lifestyle factors and MS 
disease activity. Although smoking seems to affect the MS disease progression, it 
might not directly affect MRI activity or relapse rate. Possibly, effect on 
neurodegenerative processes is the main mechanism of how smoking effect the MS 
disease course, thus explaining our negative results.  
Obesity and tobacco use have several negative health effects. Although we did not find 
a direct association with MS disease activity, these factors possess a number of other 
negative effects in MS by influencing disease progression and comorbidity. As both 
are lifestyle factors, patients may look to our results for a reason to maintain a bad 
habit. We are aware of our responsibility to always proclaim the uncertainty of our 
results, and to reflect on our finding in a bigger picture.   
The results of our second and third study indicated a suboptimal IFNβ-treatment 
response in obese patients. IFNβ- treatment has, so far, been administered as a one-
dose fits all regime, as for most DMTs. Our study may have drawn attention to this 
problem. More recently, a similar study has been conducted for pediatric patients 
supporting our findings. We hope that in the future, the role of obesity for 
pharmacokinetics in DMT and other treatments in MS will be attended, and that there 
will be individually adapted treatment protocols and BMI-adjusted dosing 
recommendations where needed. It is likely that obese patients may attain a better 
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treatment response if the dose is administered according to weight, and this can be of 
great importance for the patients, avoiding increased disease burden.  
Since the individual disease course and treatment response is somewhat unpredictable, 
there is a need for biomarkers in MS. We have explored the role of leptin and 
adiponectin and did not find these to be suitable markers. Our study indicates that their 
role in the disease pathogenesis may not be profound, and that they are not promising 
treatment targets in MS. Considering the impact of leptin in animal studies, the results 
of our study was rather disappointing, and there is still a need for more studies on the 
role of adipokines in autoimmune disease pathogenesis and course.   
Many studies are based on the OFAMS cohort, as all papers in this thesis. Recently a 
10-years follow-up study was conducted in this cohort. It may contribute to important 
information on how environmental factors effect the long-term disease course in MS.   
All together the impact of environmental factors in MS continue to be an important 
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No association of tobacco use and disease
activity in multiple sclerosis
ABSTRACT
Objective: To study whether tobacco use is associated with MRI and clinical disease activity in
patients with multiple sclerosis (MS).
Methods: Prospective cohort study of 87 patients with relapsing-remitting MS originally included
in a randomized placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS Study). Serum
levels of cotinine (biomarker of tobacco use) were analyzed at baseline and every 6 months for
2 years. MRI activity was assessed at baseline and monthly for 9 months and after 12 and
24 months.
Results: Fifty-three patients (61%) had serum cotinine levels $85 nmol/L on $60% of the meas-
urements and were considered tobacco users and 34 (39%) had cotinine levels ,85 nmol/L,
consistent with non–tobacco use. There was no association between tobacco use and the occur-
rence of new gadolinium-enhancing T1 lesions, new or enlarging T2 lesions, or their aggregate
(combined unique activity). Furthermore, there was no association between cotinine levels and
MRI activity for the tobacco users, and tobacco users did not have more relapses or Expanded
Disability Status Scale progression.
Conclusion: Our results indicate that tobacco use does not directly influence MRI activity or
relapse rate in MS. This may implicate that the reported association between smoking and MS
disease progression could be mediated through other mechanisms. Neurol Neuroimmunol
Neuroinflamm 2016;3:e260; doi: 10.1212/NXI.0000000000000260
GLOSSARY
BMI 5 body mass index; CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; HLA 5 human leukocyte
antigen; IFN-b-1a 5 interferon beta-1a; MS 5 multiple sclerosis; OR 5 odds ratio; RRMS 5 relapsing-remitting multiple
sclerosis; SPMS 5 secondary progressive multiple sclerosis; T1Gd 5 T1-weighted gadolinium-enhanced.
Multiple sclerosis (MS) is an inflammatory disease of the CNS. The etiology is unknown, but
there seems to be an interaction between genetic and environmental risk factors.1 Several human
leukocyte antigen (HLA) subtypes are known to increase the risk of MS,2 and several environ-
mental factors such as low serum vitamin D levels, Epstein-Barr virus infection, and smoking are
associated with MS.3,4
Smoking is a known risk factor for developing MS.3,5–8 Smokers with clinically isolated
syndrome have been reported to have earlier progression to clinically definitive MS than non-
smokers,9 and smoking has been suggested to decrease the time for disease conversion from
From the Department of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of
Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.),
Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of
Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.S.B.), Akershus University Hospital, Lørenskog; Institute of Clinical
Medicine (T.H., J.S.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis
Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University
Hospital; Department of Laboratory Medicine (K.S.B.), Children’s and Women’s Health, Norwegian University of Science and Technology,
Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian
University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo
University Hospital Rikshospitalet, Norway.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing
Charge was paid by the University of Bergen.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially.
Neurology.org/nn © 2016 American Academy of Neurology 1
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
relapsing-remitting MS (RRMS) to secondary
progressive MS (SPMS).10–14 It has been sug-
gested that smoking influences the clinical
progression in MS and several studies have
explored this, with conflicting results.12,15,16
One study has reported that smoking cessation
decreases the risk of Expanded Disability Sta-
tus Scale (EDSS) progression,14 but a recent
report did not find any association between
tobacco use and MS activity or progression
over a 5-year follow-up.17
To address the effect of tobacco use in es-
tablished MS, we examined the associations
among serum cotinine levels, MRI, and clini-
cal disease activity in a 2-year longitudinal
study of 87 HLA-DRB1*15–typed patients
with RRMS.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the Regional
Committee for Medical and Health Research Ethics in Western
Norway Regional Health Authority, and all participants gave
written informed consent.
Study participants and design. The study design has been
presented previously.18–20 In brief, this was a cohort study of 87
patients with RRMS according to the McDonald criteria originally
included in a randomized placebo-controlled trial of omega-3 fatty
acids at 13 Norwegian MS centers from December 2004 until July
2008 (the OFAMS [v-3 Fatty Acid Treatment in Multiple
Sclerosis] Study). Included patients had $1 clinical relapse,
a new T1-weighted gadolinium-enhanced MRI (T1Gd)-positive
lesion or enlarging T2 lesions in the last 12 months before
enrollment. The patients were followed for 24 months with
thorough examinations including serum samples, MRI scans, and
clinical scorings. MRI scans were performed at baseline and
monthly for 9 months and then after 12 and 24 months
according to a standardized protocol.18 The sum of T1Gd1
lesions and new or enlarging T2 lesions was denoted as
combined unique activity. Clinical data were recorded by
experienced neurologists, including EDSS scores every 6 months
and clinical relapses throughout the study period. The patients did
not use any immune modulatory drugs at inclusion, but from
month 6, all patients started subcutaneous injections with 44 mg
of interferon beta-1a (IFN-b-1a) (Rebif; Merck KGaA, Darmstadt,
Germany) 3 times weekly. All patients were randomized to receive
omega-3 fatty acids (Triomar; Pronova Biocare AS, Sandefjord,
Norway) or placebo (corn oil) daily throughout the study period.
Since no effects from omega-3 fatty acid supplementation on MS
disease activity were detected in any part of the study, all patients
were pooled in the current analysis.
Measurements. Cotinine is a nicotine metabolite with a half-life
of 15 to 40 hours. It is the most widely used biomarker for recent
tobacco use and has a high sensitivity (96%–97%) and specificity
(99%–100%).21 The serum levels reflect tobacco exposure during
the prior 3 to 5 days. Serum samples were stored at 280°C until
analysis, which was performed simultaneously for all samples
from each patient. The laboratory technicians were blinded for
the clinical and radiologic status of the patients. Serum levels of
cotinine were measured using liquid chromatography tandem
mass spectrometry at Bevital AS (Bergen, Norway). The
method was highly sensitive and specific with a lower limit of
detection at 1 nmol/L. The within-day coefficient of variation was
2.0% to 6.6% and the between-day coefficient of variation was
3.9%. We analyzed serum samples from patients at baseline and
months 6, 12, 18, and 24.
Cotinine levels .85 nmol/L are indicative of recent tobacco
use22 and are regarded as the optimal cutpoint widely used for
distinguishing tobacco users from non–tobacco users in the gen-
eral population.21 Cotinine has the advantage over other tobacco
biomarkers that the optimal cutpoints are little affected by the
prevalence of smoking in the population sampled.23 This is also
the cutoff value recommended by Bevital AS, the laboratory
where the serum analyses were performed.24
The patients were categorized into 2 groups according to
serum cotinine level. Patients with serum cotinine level $85
nmol/L in $60% of the samples were considered tobacco users
and patients with serum cotinine levels,85 nmol/L in$60% of
the samples were considered non–tobacco users.
The HLA-DRB1*15 analyses have been described
previously.18,20,25
Missing values. A total of 9 MRI scans (1 during study months
1–6 and 8 during study months 7–24) were missing. Seven blood
samples for serum cotinine analysis were missing for months 0 to
6 and 39 were missing for months 7 to 24.
Statistics. Data were described as frequencies and percentages or
means and SDs, as appropriate. The differences in number of re-
lapses and baseline EDSS scores among smokers and nonsmokers
were assessed using independent-samples t test.
The association between tobacco use andMRI activity was as-
sessed using a logistic regression model for hierarchical data. The
model contained fixed effect for smoking status and random ef-
fects for intercepts correctly adjusting the estimates for intrapa-
tient correlations. The model was estimated for total study
period as well as for periods before and during IFN-b-1a treat-
ment. All models were also adjusted for sex, age, body mass index
(BMI), and HLA-DRB1*15 status. The association between co-
tinine levels and MRI activity among tobacco users (serum coti-
nine$85 nmol/L) was also assessed by a logistic regression model
for hierarchical data with fixed effect for cotinine level and ran-
dom effects for intercepts.
All tests were 2-sided. Results with p values ,0.05 were
considered statistically significant. The analyses were performed
in SAS version 9.4 (SAS Institute, Cary, NC) and SPSS version
22 (IBM Corp., Armonk, NY).
RESULTS Cotinine levels and MRI disease activity. Of
87 patients, 53 (61%) had cotinine levels.85 nmol/L
in$60% of the samples and were considered tobacco
users, and 34 (39%) were considered non–tobacco
users. Most patients had consistent cotinine levels on
all samples, but 11 (13%) had consistent levels in 75%
of the measurements and 4 (5%) in 60% of the meas-
urements. There was no association between tobacco
use and MRI activity, for new T1Gd1 lesions (odds
ratio [OR] 5 0.76; 95% confidence interval [CI]
0.41–1.43; p5 0.39), for new or enlarging T2 lesions
(OR 5 0.81; 95% CI 0.42–1.56; p 5 0.52), and for
combined unique activity (OR5 0.81; 95% CI 0.43–
1.53; p 5 0.51) for the total study period. The result
was consistent for the 6 months before and 18 months
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during IFN-b-1a treatment. Adjusting for sex, age,
BMI, and HLA-DRB1*15 status did not influence
our results (table). Similarly, when only analyzing
tobacco users by logistic regression model for hierar-
chical data, there was no association between cotinine
levels and MRI activity during the 2-year follow-up
(OR 5 0.98; 95% CI 0.94–1.04; p 5 0.52).
Cotinine levels and clinical disease activity. A total of 42
relapses were recorded in 23 patients, of which 14
occurred during the first 6 study months. There was
no difference in number of relapses between the tobacco
users and non–tobacco users, with a mean number of
relapses of 0.42 (SD5 0.77) for tobacco users and 0.59
(SD 5 1.18) for non–tobacco users (p 5 0.41).
There was no difference in baseline EDSS score
between tobacco users (mean of 1.92, SD 5 0.85)
and non–tobacco users (mean of 1.85, SD 5 0.84)
(p 5 0.7). During the study period, 26 patients pro-
gressed $1 EDSS point. A total of 19 (37%) of the
tobacco users had EDSS progression compared to
7 (21%) of the non–tobacco users, but the difference
was not significant (p 5 0.14).
DISCUSSION In this cohort of patients with MS, we
could not detect any association between tobacco use,
assessed by serum cotinine levels, and MRI or clinical
disease activity.
This study was performed in a well-characterized
cohort of patients with RRMS prospectively fol-
lowed for 2 years with repeated and paired
MRI scans and measurements of cotinine levels
both before and during IFN-b-1a treatment. The
results were adjusted for sex, age, BMI, and HLA-
DRB1*15 status. All MRI, biochemical, and clin-
ical assessments were performed with strict and
standardized procedures.
There are some limitations to our study. We used
serum cotinine levels as a proxy for smoking behavior,
but being a marker for tobacco use, the levels will also
be high among snuff users or users of nicotine gum,
and one study has suggested possible protective effects
of these considering MS risk.26 The total proportion
of smokeless tobacco of all tobacco consumption in
Norway during the study period was, however, less
than 20% and even lower among women.27 It is
therefore reasonable to assume that the cotinine levels
in our samples mainly reflect smoking. The patients
were classified as tobacco users or non–tobacco users
based on cotinine level in $60% of the measure-
ments, and there is a risk of misclassification, possibly
mostly for light smokers since the half-life of serum
cotinine is 15 to 40 hours. However, we had serum
measurements at 5 different time points and most
patients had consistent serum cotinine levels on all
measurements, indicating that this is not a major
issue. It has also been demonstrated that serum coti-
nine levels are well correlated with patient-reported
smoking behavior.28 The follow-up period of
24 months is relatively short and our results might
have been different with longer follow-up. However,
our findings are in coherence with those of a recently
published study with a follow-up period of 5 years.17
Also, the lack of any of the results being even close to
significant toward influence of tobacco use on MRI
disease activity make it unlikely that there is any asso-
ciation. Our MRI findings were supported by no
association between cotinine levels and clinical disease
activity. The follow-up period was short and few re-
lapses were reported, thus the sensitivity for clinical
activity is low. However, our main outcome was MRI
activity, which is a sensitive and well-known assess-
ment for subclinical disease activity.
Table Odds ratios for MRI disease activity associated with tobacco use (serum cotinine ‡85 nmol/L) in patients with relapsing-remitting
multiple sclerosis





Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value
MRI measure
New T1Gd1 lesions 0.76 (0.41–1.43) 0.39 0.80 (0.34–1.87) 0.61 0.56 (0.19–1.63) 0.28
New T2 lesions 0.81 (0.42–1.56) 0.52 0.74 (0.30–1.81) 0.74 0.85 (0.35–2.08) 0.72
CUA 0.81 (0.43–1.53) 0.51 0.75 (0.31–1.82) 0.52 0.80 (0.32–1.98) 0.62
Adjusted for sex, age, BMI, and
HLA-DRB1*15 status (n 5 81)
New T1Gd1 lesions 0.76 (0.39–1.50) 0.43 0.72 (0.28–1.81) 0.47 0.68 (0.21–2.19) 0.51
New T2 lesions 0.87 (0.43–1.75) 0.69 0.65 (0.26–1.68) 0.37 1.04 (0.40–2.72) 0.94
CUA 0.84 (0.42–1.68) 0.63 0.63 (0.25–1.61) 0.33 0.98 (0.37–2.61) 0.97
Abbreviations: BMI 5 body mass index; CI 5 confidence interval; CUA 5 combined unique activity; IFN-b 5 interferon beta; T1Gd 5 T1-weighted
gadolinium-enhanced.
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The lack of any association between smoking and
EDSS progression in our study could be attributable
to the relatively short follow-up time of 24 months,
and the fact that few patients experienced EDSS pro-
gression during the study period. A number of earlier
studies have reported increased risk of disease progres-
sion among smokers.14,15 The mechanism for this
association is largely unknown, but one possibility
could be that smoking increases the inflammatory
activity in MS. It has been demonstrated in the exper-
imental autoimmune encephalitis model of MS that
proinflammatory T cells are activated in the lungs
before they attack the brain.29 Although our negative
results may implicate that this mechanism does not
have a major role in patients with established MS,
they do not exclude this possibility, or that smoking
has an important role during the initiation phase of
the disease. Smoking is one of the most attractive and
studied environmental risk factors for MS. The first
reports on an association between MS and smoking
were published in the 1990s,30,31 and since then,
a number of studies have confirmed smoking as a risk
factor for MS.5–7,26,32 Even passive smoking has been
associated with MS.33 Recent studies have also
described the association between cotinine levels in
serum and the risk of MS.34,35 Previous reports have
found an association with clinical disease and earlier
progression from clinically isolated syndrome to
RRMS and from RRMS to SPMS among smok-
ers.10–13,36 However, others have not been able to
confirm an association between smoking and the risk
of MS or an earlier progression to SPMS in smok-
ers.16,37 Only a few studies have examined how smok-
ing influences disease activity in MS. One study
explored the association between MRI lesions in
MS and smoking and found that the T2-weighted
lesion volume increased faster in smokers,10 and
a recently published study reported no association
between MRI activity and serum cotinine levels.17
The result of our study supports this latter report.
Other hypothesized mechanisms of adverse effects
of smoking in MS include chronic cyanide intoxica-
tion leading to demyelination, the direct effect of
cigarette-smoke components on the blood–brain bar-
rier and smoking-mediated increased frequency and
persistence of infections.11 There are also several other
possible reasons for the increased impairment and
disability in patients with MS who smoke and it is
not clear whether it is a direct effect of tobacco use or
a consequence of comorbidities associated with
smoking.38
Our results do not support a short-term (2 years)
influence of tobacco use on MRI and clinical disease
activity in MS. Long-term effects and the importance
of comorbidities influenced by smoking in MS need
to be explored.
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Obesity is a possible risk factor ofmultiple sclerosis (MS), but the association between obesity andMS disease activ-
ity has not been explored. In a cohort of 86MS patients, 80% of overweight or obese patients (BMI ≥ 25 kg/m2) had
MRI activity compared to 48% of the normal-weight patients (BMI b 25 kg/m2) (p= 0.001) during interferon-beta
treatment. NEDA-status (no evidence of disease activity)wasdefined as a composite that consisted of absenceof any
relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-
status compared to only 13% of patients with BMI N25 (p = 0.05). This may indicate that BMI affects interferon-
beta treatment response.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
Multiple sclerosis is an autoimmune disease of the central nervous
system, caused by an interaction of genetic and environmental risk
factors. Some HLA-alleles, low serum vitamin D levels, Epstein–Barr
virus infection and smoking are all factors associated with increased
MS risk (Sawcer et al., 2014; Ascherio and Munger, 2007). Obesity has
also been suggested as a possible risk factor for MS, and during the
last decade, several publications have reported an association between
higher BMI in youth and early life and MS (Munger et al., 2009, 2013;
Hedstrom et al., 2012; Wesnes et al., 2014; Langer-Gould et al., 2013).
Obesity induces a state of low-grade chronic systemic inflammation
(Overs et al., 2012). It is awell-known risk factor formultiple conditions
including cardiovascular and related metabolic disorders and some
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formsofmalignancies, and has also been associatedwith anunfavorable
course of several autoimmune diseases (Versini et al., 2014). Obesity in
female MS patients at the time of diagnosis is associated with a relaps-
ing course at disease onset (Marrie et al., 2011). Obesity is also associat-
ed with a greater risk of depression, lower functional capacity and
worse self-rated health status among MS patients (Taylor et al., 2014;
Cambil-Martin et al., 2014). Recently, a positive correlation between
BMI and disability evaluated by Expanded Disability Status Scale
(EDSS) was reported (Oliveira et al., 2014). So far no study has explored
the association between BMI and disease activity, or whether BMI influ-
ences the response to interferon-beta (IFNβ)-treatment in RRMS.
The main aim of this study was to explore if BMI has an impact on
clinical and MRI disease activity in untreated patients with RRMS and
during IFNβ -therapy. Based on the association of BMI with systemic in-
flammation as well as the role of inflammation and vitamin D status in
MS disease progression, we also explored possible associations between
BMI and selected inflammatory markers and serum vitamin D.
2. Material and methods
2.1. Study population and design
Thiswas a prospective study of 86 patientswith RRMS followed for a
total of 24 months with repeated serum analyses, MRI scans and EDSS
assessments (Table 1). The patients were included in the original
OFAMS-study, a randomized double-blind, placebo-controlled multi-
center trial of omega-3 fatty acids including 92 Norwegian patients
with RRMS according to the McDonald criteria. The patients were
aged 18–55 years with an EDSS score ≤5, and ≥1 relapse or new T1-
weighted gadolinium enhancing (T1Gd+) or T2-weighted (T2) lesion
onMRI in the year prior to inclusion. They did not receive any immuno-
modulatory therapy at inclusion and the first 6 months, but thereafter
all patients received 44 μg IFNβ subcutaneous injections three times
weekly. No effects fromω-3 fatty acids supplementation on MS disease
activitywere detected, and all patientswere therefore pooled in the cur-
rent analysis (Torkildsen et al., 2012).
2.2. Measurement of inflammation markers and 25-hydroxyvitamin D
Serum samples were collected at baseline and after 1, 3, 6, 7, 9, 12, 18
and 24months and stored at−80 °C until analysis. 25-hydroxyvitamin D
was measured with a radioimmunoassay kit (ImmunoDiagnostic Sys-
tems, Boldon, UK). The concentrations of osteoprotegerin (OPG), soluble
tumor necrosis factor receptor 1 (sTNFR1), the chemokines CXCL16 and
CCL21, transforming growth factor (TGF)β1, pentraxin 3 (PTX3), matrix
metalloproteinase 9 (MMP-9), interleukin-1 receptor antagonist (IL-
1Ra), osteopontin (OPN), and activated leukocyte cell adhesion molecule
(ALCAM) were measured by enzyme immunoassay (EIA) obtained from
R&D systems (Stillwaters, MN) as described (Holmoy et al., 2013). The
analyses were performed simultaneously for all samples from each pa-
tient. For each marker consecutive samples from each patient were
analyzed in neighboring wells on the same plate. The lab technicians
were blinded for treatment as well as MRI activity. The intra- and inter-
assay coefficient of variation were b10% for all EIAs.
2.3. HLA-DRB1 typing
The HLA-DRB1 status was determined by DNA sequencing using
SeCoreLoc DRB1 SEQ kit (Invitrogen, Carlsbad, CA, USA) at the Depart-
ment of Immunology, Oslo University Hospital, Rikshospitalet. Patients
carrying at least one DRB1*15 allele were considered HLA-DRB1*15
positive.
2.4. Body mass index (BMI)
Height and weight were registered for all patients at inclusion, and
BMI was calculated as weight/height2. The patients were categorized
based on the WHO classification of obesity into three groups; Normal
weight patients, (BMI b 25 kg/m2); Overweight patients (BMI 25–
30 kg/m2); Obese patients (BMI N 30 kg/m2). For some analyses, over-
weight and obese patients were merged into one group.
2.5. MRI
MRI was performed at baseline, monthly for 9 months and after
12 and 24 months according to a standardized protocol comprising
T2-weighted and T1-weighted gadolinium enhancing (T1Gd+)
scan using a standard head coil with a 1,5 Tesla MRI unit. Blinded
assessments of new T1Gd+ lesions and new or enlarging T2 lesions
were conducted by 2 experienced neuroradiologists. The sum of T1Gd+
lesions and new or enlarging T2 lesionswas denoted as combined unique
activity (CUA).
2.6. Composite score of no evidence of disease activity (NEDA)
NEDA was defined as a composite that consisted of absence of any
relapses, no evidence of sustained disability progression and noMRI ac-
tivity (new T1Gd+ or new/enlarging T2-lesions) on MRI examinations
for the given period (Rotstein et al., 2015). A relapse was defined as the
appearance of new symptoms or signs that lasted more than 24 h with-
out concurrent fever or illness. Progression was defined as an EDSS
score increase of 1 ormore recorded at a clinical visit thatwas sustained
at the subsequent clinical visit 6 months later.
2.7. Statistics
MRI activity was dichotomized to 0 (no activity) and 1 (activity) be-
fore the analyses. As the distribution of the inflammation markers was
skewed, all markers were LN-transformed for the statistical analyses.
Datawere described asmeans and standard deviations (SD) or frequen-
cies and percentages, as appropriate.
The association between BMI and MRI activity before and during
IFNβ-treatmentwas assessed by logistic regressionmodel for hierarchi-
cal data. The model contained random effects for patients and fixed ef-
fects for BMI-categories, dummy identifying before-during IFNβ
period and the interaction between the two. The resultswere presented
as odds ratios (ORs) with corresponding 95% confidence intervals (CI)
within each BMI category (normal weight group as reference) before
and during IFNβ-treatment as well as ORs for decrease in MRI activity
from before to during IFNβ-treatment period. The ORswere also adjust-
ed for age and HLA-DRB1*15 status.
The association between continuous BMI and inflammationmarkers
was estimated by a linearmixedmodelwith random effects for patients
and fixed effects for BMI. The results were reported as regression coeffi-
cients with the corresponding 95% CI. The change in inflammation
markers from before to during IFNβ-treatment was compared between
two BMI categories by estimating a linear mixed model with random
Table 1
Clinical, MRI and laboratory measurements during study period.
Month




MRI examination • • • • • • • • • • • •




• • • • • • • • •
MRI = magnetic resonance imaging; EDSS = Expanded Disability Status Scale. Relapses
were recorded throughout the study period.
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effects for patients andfixed effects for BMI categories, dummy identify-
ing before-during IFNβ period and the interaction between the two.
The association between seasonally adjusted vitamin D status and
continuous BMI was assessed by estimating a linear mixed model with
random effects for patients and fixed effects for vitamin D.
Explorative analyses of MRI activity within different categories of
BMI status, (b25 kg/m2 and ≥25 kg/m2) as well as NEDA-status were
assessed by z-test for proportions and independent samples t-test. For
multiple comparisons, one-way analysis of variance (ANOVA), followed
by Fishers' least significant difference method was used as post hoc
analysis where applicable. All analyses were performed in SPSS 22 and
SAS 9.3. The results with p-values below 0.05 were considered statisti-
cally significant. All tests were two-sided.
3. Results
3.1. BMI and disease activity before IFNβ-treatment
The mean BMI in our cohort was 25.7 kg/m2 (±SD 0.47). There
were 46 normal weight patients, 23 overweight patients and 17 obese
patients. The mean EDSS scores at inclusion were not correlated with
BMI (1.94 ± 0.90 for normal weight patients, 1.83 ± 0.78 for over-
weight patients and 1.82 ± 0.71 for obese patients, p = 0.57). During
the 6 treatment-free months, 10 patients progressed ≥1 EDSS score,
comprising 6 normal weight patients and 4 overweight or obese
patients. There were a total of 14 clinical relapses in 11 patients,
which included 4 normal weight patients and 7 overweight or obese
patients. There was no significant association between BMI andMRI ac-
tivity (CUA) during the six months prior to IFNβ-treatment (Table 2).
Adjusting for gender and HLA-DRB1*15 status did not influence our
results (data not shown). To increase the power to detect significant
differences, we pooled the groups of overweight and obese patients
(n = 40), and found a similar pattern with no association between
BMI and MRI disease activity (Suppl. Table 1). The mean proportion of
positive MRI scans in the period before treatment was 47% for the nor-
mal weight patients, 57% for the overweight patients and 43% for the
obese patients (Suppl. Figure 1). At baseline 22 (55%) of the overweight
and obese patients hadMRI activity compared to 22 (48%) of the normal
weight patients (p = 0.72). Most patients had active disease in the
treatment-free period, for the number of patients without MRI activity,
clinical relapses or EDSS progression during the 6 months there were 6
(15%) overweight or obese patients and 12 (26%) normal weight
patients (p = 0.43).
3.2. BMI and disease activity during IFNβ-treatment
A total of 28 relapses were recorded in 19 patients during IFNβ-
treatment, which included 9 normal weight patients and 10 overweight
and obese patients. Twenty-five patients progressed ≥1 EDSS points
during the whole study period. All patients had a significant reduction
in MRI disease activity (CUA) after initiation of IFNβ-treatment (p ≤
0.001) (Suppl. Table 2). There was no significant difference between
the groups and this was consistent after adjusting for gender and HLA-
DRB1*15 status, and after merging the groups of overweight and
obese patients (Suppl.Table 1). There were, however, significant
differences in the number of patients without MRI activity, clinical
relapses or EDSS progression during treatment, in relation to BMI.
Thus, for patients with normal weight, 24 patients (52%) had no sign
of MRI activity (CUA) during the entire treatment period compared to
only 8 patients (20%) with overweight or obesity (p = 0.001)
(Fig. 1A). The proportion of patients with noMRI activity and no clinical
relapses combined was 41% in the normal weight group compared to
18% in those with overweight or obesity (p= 0.01) (Fig. 1B). Including
Table 2
Odds ratio forMRI disease activity (New T1Gd+ lesions or new or enlarging T2 lesions) in






OR (95% CI) p-Value OR (95% CI) p-Value
b25 kg/m2 (n = 46) 1 1
25–30 kg/m2 (n = 23) 1.49 (0.63–3.51) 0.36 2.44 (0.96–6.15) 0.06
N30 kg/m2 (n = 17) 0.78 (0.30–2.04) 0.62 1.18 (0.40–3.47) 0.77 Fig. 1.A. Proportion of patientswithout newT2 and/or T1Gd+MRI lesions. B. Proportion of
patients without MRI activity or clinical relapses. C. Proportion of patients with NEDA*.
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also EDSS progression, showed that 26% in the normal weight group
obtained NEDA-status, compared to only 13% in the group of over-
weight and obese patients (p = 0.05) (Fig. 1C).
3.3. BMI and the level of inflammation markers and vitamin D
We have previously reported an association between MRI disease
activity and different inflammation markers in this cohort (Holmoy
et al., 2013). Based on these data, we explored the correlation between
inflammationmarkers and BMI. There was a significant inverse correla-
tion between BMI and serum level of PTX3(r=−0.4, p = 0.003) and a
positive correlation with IL-1Ra (r= 0.08, p= 0.005), but not with any
of the other inflammatory markers. (Table 3). We further investigated
how IFNβ–treatment affected the inflammation markers and found an
overall equal response for normal weight, overweight and obese
patients, including a parallel increase in the serum levels of IL-1Ra and
PTX3 during treatment (Table 4). There was no correlation between
BMI and seasonally adjusted vitamin D levels in serum, (r = 0.04;
p = 0.9).
4. Discussion
In this study, we found that overweight and obese patients had
higher disease activity, as evaluated by NEDA-status, during IFNβ-
treatment compared to normal-weight patients. There was no associa-
tion between BMI and MRI disease activity before IFNβ -treatment
and we did not find any difference in disability (EDSS) progression be-
tween the groups although this has been reported in another study
(Oliveira et al., 2014). The mean BMI in our cohort was 25.7 kg/m2.
This is lower than themean BMI in theNorwegian population, but in co-
herence with the findings of BMI for MS patients in Norway (Nortvedt
et al., 2005).
Obesity is associated with a low-grade inflammatory state and
release of cytokines that influence immune responses (Cao, 2014). It
has been shown to worsen the disease course in several autoimmune
diseases (Versini et al., 2014) and studies have reported a positive asso-
ciation between BMI and disability among MS patients (Oliveira et al.,
2014). Adiposity induces a pro-inflammatory macrophage profile in
the fatty tissue (Lumeng et al., 2007) and a study of experimental auto-
immune encephalomyelitis (EAE) in mice showed more relapses in
mice with this macrophage profile (Mikita et al., 2011).
There was a significant reduction in MRI disease activity in all three
BMI-groups during IFNβ-treatment (Suppl. Table 2). However, there
was a significant difference between normal weight and overweight-
and obese patients regarding the number of patients obtaining NEDA-
status. Our results indicate that overweight and obesity may have an
impact on IFNβ-treatment response. It is uncertain whether this may
be due to a suboptimal treatment response among overweight and
obese patients or a generally more active disease in these groups. How-
ever, the IFNβ-treatment had a similar response on the levels of inflam-
mation markers for all patients. This may indicate that the difference in
treatment response was not due to a lesser effect on the inflammation.
Different BMI between patients is not accounted for in routine IFNβ-
treatment regimens since all patients receive the same dose. Most stud-
ies on IFNβ-treatment have not addressed the issue of BMI (Clanet et al.,
2002; Kalincik et al., 2013; Kappos et al., 2004) and others have found
conflicting results regarding the effect of different doses of IFNβ, howev-
er not adjusting for BMI (Li and Paty, 1999; O'Connor et al., 2009). Only
one study has explored the effect of BMI regarding IFNβ-treatment, but
this was a study on treatment of secondary progressive MS (SPMS)
reporting no effect of IFNβ-treatment overall (Panitch et al., 2004).
We did not find an association between BMI and MRI activity for the 6
months without treatment, possibly due to low numbers of patients in
each group and large variation in MRI disease activity.
Obesity may influence systemic inflammation, and in the present
study we found an inverse correlation between serum PTX3 levels, an
acute-phase protein produced at the site of inflammation, and BMI.
Our results are in accordance with a recent study reporting an inverse
association between serum PTX3 levels and BMI in the general popula-
tion (Witasp et al., 2014). However, increased PTX3 levels are observed
in several autoimmune disorders (Shimada et al., 2014). A previous
study found that plasma levels of PTX3 inMS patients were significantly
increased duringMS relapses (Wang et al., 2013), suggesting that a link
Table 3
Correlation between inflammation markers and BMI during the study period.
Inflammation marker Regression coefficient (95% CI) p-Value
PTX3 −0.4 (−0.06; −0.01) 0.003
sTNFR1 0.006 (−0.007; 0.019) 0.35
CXCL16 0.008 (−0.01; 0.03) 0.38
MMP-9 0.01 (−0.03; 0.05) 0.49
CCL21 0.008 (−0.01; 0.03) 0.46
IL-1RA 0.08 (0.03; 0.14) 0.005
OPN −0.004 (−0.03; 0.02) 0.79
OPG 0.0006 (−0.01; 0.01) 0.92
sFRP3 0.004 (−0.03; 0.04) 0.84
TGFβ1 0.01 (−0.003; 0.03) 0.11
ALCAM 0.005 (−0.01; 0.02) 0.59
PTX3, pentraxin 3; sTNFR1, soluble tumor necrosis factor type 1; CXCL16, chemokine (C-X-C
motif) ligand 16; MMP-9, matrix metalloproteinase 9; CCL21, chemokine (C-C motif) ligand
21; IL-1Ra, interleukin-1 receptor antagonist; OPN, osteopontin; OPG, osteoprotegrin; sFRP3,
secreted frizzled-related protein 3; TGFβ1, transforming growth factor β1; ALCAM, activated
leukocyte cell adhesion molecule. Bold figures indicate p ≤ 0,005.
Table 4
Effect of IFNβ-treatment on serum inflammationmarkers in patients categorized into two
groups, normal weight (BMI b 25 kg/m2) and overweight or obese (BMI ≥ 25 kg/m2).
Inflammation
markers




N = 25 kg/m2
(n = 40)
BMI b 25 kg/m2 vs.
BMI ≥ 25 kg/m2
LN_PTX3
Before 7.0 (6.9; 7.2) 6.7 (6.6; 6.9) 0.18
During 7.1 (6.9; 7.2) 6.8 (6.7; 7.0)
LN_sTNFR1
Before 6.8 (6.7; 6.9) 6.8 (6.7; 6.9) 0.22
During 6.9 (6.8; 7.0) 6.9 (6.8; 7.0)
LN_CXCL16
Before 7.0 (6.9; 7.1) 7.0 (6.9; 7.2) 0.05
During 7.1 (7.0; 7.3) 7.2 (7.1; 7.4)
LN_MMP9
Before 5.9 (5.7; 6.2) 6.2 (6.0; 6.5) 0.13
During 5.6 (5.3; 5.8) 5.7 (5.4; 5.9)
LN_CCL21
Before 5.6 (5.5; 5.8) 5.6 (5.5; 5.8) 0.14
During 5.8 (5.6; 5.9) 5.8 (5.6; 5.9)
LN_IL1RA
Before 3.5 (3.1; 3.8) 4.1 (3.7; 4.4) 0.46
During 4.1 (3.7; 4.4) 4.6 (4.2; 4.9)
LN_OPN
Before 1.8 (1.7; 2.0) 1.9 (1.7; 2.1) 0.46
During 2.2 (2.1; 2.4) 2.3 (2.1; 2.5)
LN_OPG
Before 6.9 (6.9; 7.0) 6.9 (6.8; 7.0) 0.16
During 7.1 (7.0; 7.2) 7.1 (7.0; 7.1)
LN_sFRP3
Before 8.3 (8.0; 8.5) 8.2 (8.0; 8.5) 0.48
During 8.3 (8.1; 8.6) 8.3 (8.0; 8.5)
LN_TGFβ1
Before 2.9 (2.8; 3.0) 3.0 (2.9; 3.1) 0.47
During 2.8 (2.7; 2.9) 2.9 (2.8; 3.1)
LN_ALCAM
Before 5.0 (4.9; 5.1) 5.1 (4.9; 5.2) 0.69
During 5.0 (4.9; 5.1) 5.1 (5.0; 5.2)
PTX3, pentraxin3; sTNFR1, soluble tumor necrosis factor type 1; CXCL16, chemokine C-X-C
motif ligand 16; MMP-9, matrix metalloproteinase 9; CCL21, chemokine C-C motif ligand
21; IL-1Ra, interleukin-1 receptor antagonist; OPN, osteopontin; OPG, osteoprotegrin;
sFRP3, secreted frizzled-related protein 3; TGFβ1, transforming growth factor β1;
ALCAM, activated leukocyte cell adhesion molecule.
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between high BMI andMS activity did not involve PTX3 related mecha-
nisms.We also detected a correlation between serum level of IL-1Ra and
BMI. IL-1Ra is a cytokine antagonist secreted by immune cells and
adipocytes that inhibits the binding of IL-1 to its receptor. InMS circulat-
ing levels have been shown to correlate with disease activity and IFNβ-
treatment and it has been suggested involved in the counter-regulation
of inflammatory activity (Voltz et al., 1997; Nicoletti et al., 1996). The
serum level of IL-1Ra is known to be higher among overweight and
obese patients (Meier et al., 2002), which we also found in our cohort.
Again, our findings suggest that any link between obesity and enhanced
MS activity seem not to involve IL-1Ra related mechanism.
The strengths of this study were that the analyses were done in a
well characterized cohort of patients with RRMS. The study had a pro-
spective studydesignwith repeated andpairedMRI scans andmeasure-
ments of serum levels before and during IFNβ-treatment. All MRI,
biochemical and clinical assessments were performed with strict and
standardized procedures. The main limitation of our study is that the
numbers of patients in each group were small, implying limited power
to detect small differences between the groups. Further we only mea-
sured BMI at inclusion, and there is a possibility that patients may
have changed BMI status during the study period of two years. More-
over, a number of parameters were investigated in this cohort, and the
possibility that some of the significant findings are by chance should
be taken into account. Several reports have found a correlation between
circulating levels of vitamin D and obesity (Konradsen et al., 2008;
Wortsman et al., 2000). There was however no evidence for this in
our cohort. This may be explained by different study populations.
Most of the studies reporting an association are based on subjects
with morbid obesity and BMI N35 kg/m2. The number of patients with
BMI N 30 kg/m2 was also small and there might be an association that
we did not find because of these low numbers.
The low number of morbidly obese patients may also explain why
we did not find any correlation between most of the inflammation
markers and BMI. Obesity and metabolic syndrome are known to effect
serum inflammation markers (Cao, 2014; Park et al., 2005). Our cohort
included only one patient with BMI N35 kg/m2 and we do not know if
any patients had metabolic syndrome. Further, the choice of inflamma-
tion markers for analyzes was made in a previous study on this cohort
emphasizing markers that are likely to reflect different steps in the
pathogenesis ofMS, andmay not necessarily reflect systemic inflamma-
tion associated with it. Increased levels of inflammation markers like
tumor necrosis factor α (TG1α), interleukin-6 (IL-6) and adipokines
have been reported in obese patients (Cao, 2014), but were not exam-
ined in our study. There is a possibility that we would have found a cor-
relation with BMI and a difference in serum level during treatment had
other more obesity-related markers been tested.
5. Conclusion
Obesity has a major effect on several diseases and effect the risk of
MS. This study indicates that patients with overweight and obesity has
a lesser chance of obtaining complete remission and NEDA-status
during IFNβ-treatment. Whether this is due to a suboptimal treatment
response or a generally more active disease remains to be determined.
Our findings suggest that BMI should be taken into account when eval-
uating the effect of IFNβ-treatment in MS patients and should also
encourage weight reducing measures as part of the therapy in over-
weight and obese patients. It also emphasizes a need for further studies
on this issue.
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No evidence of disease activity
Treatment response
A B S T R A C T
Adipokines secreted by fatty tissue have inflammatory properties and are suggested biomarkers of MS disease
activity. To assess this, 88 MS patients were followed with nine repeated measurements of leptin and adiponectin
and 12 magnetic resonance imaging (MRI) scans for two years; six months without any immunomodulatory
treatment followed by 18months during interferon-beta (IFNB) treatment. Serum levels of leptin dropped and
adiponectin increased upon initiation of IFNB-therapy, but were not associated with clinical or MRI disease
activity or with treatment response. Our findings indicate that leptin and adiponectin are not useful as bio-
markers of MS disease activity.
1. Introduction
Multiple sclerosis is a neuro-inflammatory disease caused by an
interaction of genetic and environmental factors (Thompson et al.,
2018; Huynh and Casaccia, 2013). Obesity increases the risk of MS and
has been reported to affect disability and relapse rate (Munger et al.,
2009; Munger et al., 2013; Hedstrom et al., 2012; Langer-Gould et al.,
2013; Wesnes et al., 2015; Marrie et al., 2011; Oliveira et al., 2014;
Cortese et al., 2018). In an earlier study, we showed that body weight
influenced interferon-beta (IFNB) treatment response, as fewer of the
overweight MS patients achieved NEDA-status compared to patients
with normal weight (Kvistad et al., 2015). The mechanism for this re-
mains unclear.
Obesity induces a chronic state of low-grade inflammation and is
known to affect onset and progression of several autoimmune diseases
(Versini et al., 2014). Adipokines are produced by adipocytes in the
fatty tissue and are involved in the regulation of inflammation and
immune responses (Tilg and Moschen, 2006). The role of serum adi-
pokine levels has been explored for several autoimmune diseases with
various results (Otero et al., 2006; Lee and Song, 2018; Mei et al., 2016;
Li et al., 2015; Cao et al., 2016). Both clinical and experimental studies
have described findings supportive of a link between metabolic status
and the immune system in the pathogenesis of MS (Matarese et al.,
2010). Especially two adipokines have been explored in MS, adipo-
nectin and leptin, which also represent the most abundant adipokines
produced by adipocytes (Guerrero-Garcia et al., 2016). Adiponectin is a
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primarily anti-inflammatory acting adipokine, and low levels are as-
sociated with worse experimental autoimmune encephalomyelitis
(EAE) (Piccio et al., 2013). Leptin has a pronounced part in the reg-
ulation of the Th1/Th2-balance, is negatively associated with the
number of regulatory T-cells and has a key involvement in the secretion
of several pro-inflammatory cytokines (Fantuzzi and Faggioni, 2000).
Several reports have described an association between leptin and the
induction and progression of EAE (Matarese et al., 2001; Sanna et al.,
2003).
Serum leptin levels has also been suggested as a biomarker of
treatment-response in relapsing-remitting MS (RRMS), (Batocchi et al.,
2003) and a recent study found an association between serum leptin
levels and MS severity and number of relapses (Lanzillo et al., 2017).
The aim of this study was to examine if adiponectin and leptin were
associated with MS disease activity and could be used as biomarkers of
MS disease activity and IFNB-treatment response.
2. Material and methods
2.1. Study population and design
The study population comprised MS patients from an omega-3 fatty
acids study in MS (OFAMS) described in previous publications
(Torkildsen et al., 2012; Kvistad et al., 2014). In brief this was a pro-
spective study of 88 RRMS patients followed for a total of 24months
with repeated serum analyses, magnetic resonance imaging (MRI) scans
and clinical (relapse and Expanded Disability Status Scale; EDSS) as-
sessments. The patients were included in the original OFAMS study,
that was a randomized double-blind, placebo-controlled multicenter
trial of omega-3 fatty acids including 92 Norwegian patients with RRMS
according to the McDonald criteria. The patients were 18–55 years of
age with an EDSS score ≤5, and ≥1 relapse or new T1-weighted ga-
dolinium enhancing (T1Gd+) or T2-weighted (T2) lesion on MRI in the
year prior to inclusion. They did not receive any immunomodulatory
therapy at inclusion and the first six months, but thereafter all patients
received 44 μg IFNB -1a subcutaneous injections three times weekly
(Torkildsen et al., 2012).
2.2. Serum adipokine analyses
Serum samples were collected at baseline and after 1, 3, 6, 7, 9, 12,
18 and 24months and stored at−80 °C until analysis. Serum-leptin and
adiponectin were measured by radioimmunoassay kit (Merc Millipore
Corporation, Hormonlaboratoriet, OUS, Norway).
The analyses were performed simultaneously for all samples from
each patient. For each marker consecutive samples from each patient
were analyzed in neighboring wells on the same plate. Each sample was
analyzed in duplicates. The laboratory technicians were blinded for
treatment as well as MRI activity.
2.3. MRI
MRI was performed at baseline, monthly for nine months and after
12 and 24months according to a standardized protocol comprising T2-
weighted and T1-weighted gadolinium enhancing (T1Gd+) scan using
a standard head coil with a 1,5 Tesla MRI unit. Blinded assessments of
new T1Gd+ lesions and new or enlarging T2 lesions were conducted
by two experienced neuro-radiologists. The sum of T1Gd+ lesions and
new or enlarging T2 lesions was denoted as combined unique activity
(CUA).
2.4. No evidence of disease activity (NEDA-3)
NEDA-3 was defined as a composite that consisted of absence of any
relapses, no evidence of sustained disability progression and no MRI
activity (new T1Gd+ or new/enlarging T2-lesions) on MRI examina-
tions for the given period (Rotstein et al., 2015). A relapse was defined
as the appearance of new symptoms or signs that lasted> 24 h without
concurrent fever or illness. Progression was defined as an EDSS score
increase of 1 or more recorded at a clinical visit that was sustained at
the subsequent clinical visit 6months later.
2.5. Missing values
A total of nine MRI scans (one during study months 1–6 and eight
during study months 7–24) were missing. Six blood samples for serum
leptin and adiponectin were missing for months 0–6 and 22 blood
samples for months 7–24 (24 for leptin).
2.6. Statistics
Data are described as means and standard deviations (SDs).
Within- and between-patient variance was estimated by a linear
mixed model (LMM) with random intercepts for patients. Mean serum
levels before and during treatment were compared by including fixed
effects for period into LMM. Associations between baseline levels of
adipokines and body mass index (BMI), relapses, NEDA and EDSS score
at baseline were assessed by linear regression model.
Generalized linear mixed models with random intercepts for pa-
tients were used to estimate the association between MRI activity and
adipokines. LMM was estimated to assess the associations between time
profile in adipokines, NEDA status and EDSS progression at baseline as
well as relapses. To compare the periods before and during IFNB-
treatment, the relevant models were re-estimated by including the in-
teraction between the period and variable of interest. All models were
also adjusted for gender, age and BMI. Intra-center correlations were
negligible hence no adjustments for cluster effect on center level were
included into the regression models. Results with p values < .05 were
considered statistically significant. The analyses were performed in SAS
version 9.4 (SAS Institute, Cary, NC) and SPSS version 25 (IBM Corp.,
Armonk, NY).
Table 1
Concentrations of adipokines in multiple sclerosis patients at different time points before and during interferon-beta treatment.
Before interferon beta treatment During interferon-beta treatment
Study months
0 1 3 6 7 9 12 18 24
Leptin, n 85 85 87 88 80 85 82 82 87
pmol/l (SD) 1038 (1031) 1013 (955) 1101 (984) 1052 (1016) 976 (782) 1054 (977) 979 (856) 926 (812) 1011 (950)
Adiponectin, n 85 86 87 88 80 86 83 82 87
mg/l (SD) 8.8 (4.0) 9.0 (4.2) 9.3 (4.3) 9.4 (4.3) 10.0 (4.8) 9.5 (5.0) 9.2 (4.3) 9.3 (4.3) 9.3 (4.5)
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3. Results
3.1. Serum levels of leptin and adiponectin
A total of 764 serum samples were analyzed in 88 patients. Mean
levels of leptin and adiponectin at baseline and during different phases
of the study are shown in Table 1. The serum leptin levels were sig-
nificantly higher (mean difference 55.7 pmol/l, 95% CI 14.5; 96.9,
p= .008) while the serum adiponectin levels were significantly lower
(mean difference 0.24mg/l, 95% CI 0.01–0.46, p= .037) before IFNB-
treatment as compared to during treatment.
The minimum serum-leptin level was 50 pmol/l and the maximum
was 6250 pmol/l. The minimum serum-adiponectin level was 0.8 mg/l
and the maximum was 31.8mg/l. There was a great inter-individual
variation in the serum levels of adipokines, but the level for each pa-
tient was relatively stable for the nine measurements during the
24months period. The maximum difference in serum-leptin was
3510 pmol/l within- and 6200 pmol/l between-patients. The maximum
difference in serum-adiponectin was 15.8 mg/l within- and 31.0 mg/l
between-patients. Close to 90% of the total variation in serum levels
could be attributed to between-patient variations. There was a positive
association between BMI and serum-leptin measured at baseline
(p < .001), but no association between BMI and serum-adiponectin
(p= .137).
3.2. Serum leptin and adiponectin levels and MRI disease activity
There was no association between the serum levels of adipokines
and MRI activity, OR for CUA=0.99 (0.99–1.00) for leptin and 1.02
(0.96–1.08) for adiponectin; p > .50 for both). The results were con-
sistent for the six months before and 18months during IFNB-treatment
(Fig. 1). Adjusting for gender, age and BMI did not influence the results.
Neither new T1Gd+ -lesions or new and enlarging T2 lesions were
associated with any of the adipokines (data not shown).
3.3. Serum leptin and adiponectin levels and clinical relapses
A total of 11 of the 88 patients (6%) had clinical relapses during the
study period. There was no differences between patients with and
without relapses in the serum-leptin (p= .70) or serum-adiponectin
levels (p= .20) at baseline, nor did the patients differ in serum adi-
pokine levels throughout the study-period. This was also consistent
after adjusting for gender, age and BMI.
3.4. Serum levels of leptin and adiponectin and EDSS score
The mean EDSS score was 1.9 (0.84) at baseline. Mean serum-leptin
and serum-adiponectin at baseline were 1037.0 (1030.6) pmol/l and
8.8 (4.0) mg/l, respectively. There was no association between serum-
leptin and EDSS score at baseline (p= .89) or between serum-adipo-
nectin level and EDSS score at baseline (p= .38).
Twenty-five patients progressed ≥1 EDSS points during the whole
study period. There was no association between EDSS progression and
baseline serum-leptin (p= .95) or adiponectin level (p= .38). There
was no difference in serum levels between patients with EDSS pro-
gression and those without progression throughout the study, and ad-
justing for age and gender did not change the results.
3.5. Serum levels of leptin and adiponectin and NEDA-3 status
Only 16 of the 88 patients (18%) obtained NEDA-3-status during
IFNB -treatment. There was no difference between patients that ob-
tained and those that did not obtain NEDA-3-status in baseline serum-
leptin or adiponectin (p= .21 and p= .33, respectively). The groups
did not differ in serum-levels throughout the study-period. This was
also consistent after adjusting for gender, age and BMI.
4. Discussion
In this study we explored the potential role of two adipokines, leptin
Fig. 1. Odds ratio for MRI disease activity (New T1Gd+ lesions or new or enlarging T2 lesions) depending on serum level of leptin and adiponectin before and
during IFNB –treatment. There was no significant difference in OR for CUA depending on the serum level of leptin or adiponectin.
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and adiponectin, as biomarkers of disease activity and IFNB-treatment
response in MS. We found no association between the serum levels of
leptin or adiponectin and MRI- and clinical disease activity or NEDA-3-
status, indicating that neither of the adipokines is useful as biomarkers
of MS disease activity or treatment-response. We did however find a
difference in serum levels of the adipokines before and during IFNB-
treatment, reflecting the anti-inflammatory effect of the drug.
Studies have shown that MS patients have higher serum levels of
leptin and lower serum levels of adiponectin than the normal popula-
tion (Kraszula et al., 2012; Matarese et al., 2005; Musabak et al., 2011;
Frisullo et al., 2007). This has been of great interest since these adi-
pokines are regulators of the immune system. Leptin acts as a pro-in-
flammatory hormone and induces Th1-cytokin production, and adipo-
nectin has anti-inflammatory properties as it suppresses synthesis of
several pro-inflammatory cytokines (tumor necrosis factor-α, inter-
leukin-6, interferon-γ) (Tilg and Moschen, 2006). Both adipokines are
important for introduction and disease progression in EAE, (Piccio
et al., 2013; Matarese et al., 2008) and there are reports supporting a
link between metabolic status and MS pathogenesis (Matarese et al.,
2010). Hence, the role of serum-leptin and adiponectin in MS has been
given much attention, but the results related to MS disease activity are
so far conflicting. A report on 59 MS patients followed for 12months
found that serum levels of leptin was increased before clinical relapses
and decreased during IFNB-treatment (Batocchi et al., 2003), opposed
to others that found higher levels during remission (Chatzantoni et al.,
2004; Frisullo et al., 2007). A recent study on 45 MS patients followed
for 12months reported that higher serum leptin levels at baseline was
associated with greater risk of clinical relapses and MRI-activity the
upcoming year, and it was proposed as a tool for prediction of disease
course during IFNB-treatment (Lanzillo et al., 2017). All these studies
included a limited number of patients and had a short follow-up time. A
prospective study of 80 patients followed for two years did however not
find any association between serum-leptin or adiponectin levels and
disease activity (Natarajan et al., 2015). This is in accordance with our
findings.
In our study, the levels of leptin were lower and the levels of adi-
ponectin higher during IFNB- treatment as compared to the treatment-
naïve period, indicating a more favorable inflammatory profile during
treatment. This was expected considering the anti-inflammatory effect
of the drug. It is also in accordance with a previous report on in-
flammation markers in this cohort, showing favorable inflammatory
changes during treatment (Holmoy et al., 2013). Changes in serum le-
vels were, however, not associated with disease activity during IFNB-
treatment and the adipokines were concluded as not useful biomarkers
for treatment response.
We have previously shown that fewer overweight and obese patients
achieved NEDA-3 status during IFNB-treatment compared to patients
with normal weight. We found that 26% of normal weight patients
obtained NEDA-status during IFNB-treatment compared to only 13% of
patients with BMI > 25 (Kvistad et al., 2015). The cause of this is
unknown, but overweight is associated with a chronic low-grade in-
flammation, and variable levels of adipokines have been suggested to
contribute to a pro-inflammatory status associated with fewer reg-
ulatory T-cells and cytokine-release (Guerrero-Garcia et al., 2016; Cao,
2014). We aimed therefore to explore whether the differences in
treatment response was associated to different serum levels of adipo-
kines. We found no association between serum levels of leptin or adi-
ponectin and treatment response.
In our cohort there was no association between serum levels of
leptin and adiponectin and baseline EDSS score, and the serum levels
did not differ between patients regarding their disease course assessed
by clinical relapses or achievement of NEDA-status. One study of 110
MS patients described an association between obesity in MS and EDSS
score in the setting of insulin-resistance (Oliveira et al., 2014) and one
study of 45 MS patients described a non-significant correlation between
serum-leptin and EDSS score (Lanzillo et al., 2017). However, most
studies are coherent with our findings and report no correlation be-
tween EDSS score and serum leptin or adiponectin (Chatzantoni et al.,
2004; Batocchi et al., 2003; Rotondi et al., 2013; Natarajan et al., 2015;
Evangelopoulos et al., 2014).
The OFAMS study consisted of a cohort that was very well char-
acterized over a two year-period with nine serum measurements and 12
MRI examinations for each patient. All MRI, biochemical and clinical
assessments were performed with strict and standardized procedures.
The cohort has been explored in great extent with many published re-
ports where factors proven to be associated with disease activity, like
vitamin-D level and Epstein-Barr virus antigen levels have been con-
firmed (Loken-Amsrud et al., 2012; Kvistad et al., 2014). There are
however some limitations. The number of overweight patients was ra-
ther small, and only 18% of these obtained NEDA-status. Hence there is
a possibility that the number of patients were too low to find an asso-
ciation between serum-leptin levels and treatment-response after ad-
justing for BMI. However the vast majority of other reports on MS and
adipokines have included fewer patients. Another weakness with our
study was that only one patient had BMI > 35 kg/m2, and the group of
overweight patients were not characterized regarding insulin-resistance
and metabolic syndrome. It is likely that the grade of inflammation and
level of adipokines would have been different in a group of morbidly
obese patients with comorbidities, and we cannot be sure that our re-
sults can be applied under such circumstances. However, in Europe
RRMS patients with BMI > 35 are uncommon. The patients in this
study were randomized to omega 3 fatty acids or corn oil. There have
been reports on a relation between the serum levels of leptin and adi-
ponectin and omega-3 fatty acids, where omega 3 fatty intake can de-
crease circulating levels of leptin in non-obese subjects and increase the
levels in obese patients (Gray et al., 2013). This is a possible confounder
in our study. However, considering that we wanted to explore if higher
leptin levels could possibly explain why less obese patients obtained
NEDA-status in our previous study compared to normal weight patients,
the possible changes induced by the omega-3 fatty acid would be likely
to influence our results so that we would have found a greater differ-
ence. Since we did not find any effects of serum leptin levels, we assume
that this is not a major confounder in our study. Several factors may
affect serum leptin-levels included fasting, emotional stress, physical
exercise and diurnal variation with higher levels at early morning and
during night. The serum-leptin levels vary during the day and are
higher at night and early morning. This may have affected our results,
but most probably only to a minor degree. The blood samples were
collected mainly at equal time points during daytime. The intra-in-
dividual variance was also low in this material.
5. Conclusion
Our findings indicate that serum-leptin and adiponectin do not have
a profound role in the immune mechanisms of RRMS-disease activity,
and are therefore not suitable as potential biomarkers of disease activity
or IFNB-treatment response.
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